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Abstract 
G-quadruplex DNA represents an attractive target for the development of anti-cancer 
therapeutic agents as it plays important roles in transcriptional regulation and the maintenance of 
telomeric length. Oxazole-containing macrocycles such as telomestatin are considered to be a 
promissing new class of G-quadruplex binding ligands. In this work, poly-oxazole building blocks 
were synthesized to prepare a tetraoxazole peptide macrocycle in good yield. The macrocycle was 
obtained by employing standard peptide coupling conditions using a convergent solution phase 
approach. The synthetic unit of the oxazole amino acid containing compound was prepared by 
cyclodehydration/oxidation of protected serine and phenylalanine. Two-cycle coupling of the unit 
gave a linear tetraoxazole amide. The final macrocyclization was accomplished by using O-[(1-
cyano-2-ethoxy-2-oxoethylidene)amino]-oxytri(pyrrolidin-1-yl) phosphonium hexafluorophosphate 
(PyOxP) and the product (45% yield) was characterized by 
1
H NMR. Finally, the Cu (II) 
coordination chemistry of the tetraoxazole macrocycle was investigated by spectrophotometric 
titration. 
 
Keywords 
G-quadruplexes, telomestatin, poly-oxazole macrocycles, macrocyclization, dinuclear copper (II) 
complex. 
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1. Introduction  
1.1. General Review of Telomeres 
Telomeres are the deoxyribonucleic acid (DNA) sequences at the end of linear 
chromosomes. They play a vital role in preserving genetic integrity within the nucleus by protecting 
the ends of the chromosomal DNA from degradation or fusion, and in segregating the chromosomes 
during cell division. Telomeres are comprised of specific sequences of certain repetitive patterns 
that depend on the organism. For example, in humans, there are several thousands of TTAGGG 
repetitive sequences at the ends of the chromosomes.
1
 This repetitive hexanucleotide is present on 
the 5’-3’ strand. During the replication of chromosomes, the lagging strand replicates these G-rich 
repetitive sequences. Due to the discontinuous replication pattern in the lagging strand, there is a 3’ 
single–stranded overhang varying in length from 24 to 360 nucleotides.2 Studies have shown that 
the 3’ single-stranded telomeric overhang forms a ‘t’-loop structure that interacts with the internal 
TTAGGG repeats of the telomere. Moreover, the telomeric DNA does not form nucleosomes as a 
result of the lack of typical nucleoproteins, which are required to arrange nuclear DNA into 
nucleosomes.
3
 Rather, the interaction of specific types of proteins, which are Telomeric Repeat 
Factor 1 (TRF1) and Telomeric Repeat Factor 2 (TRF2), stabilize the DNA at the telomeres by 
forming specific nucleoprotein complexes. These nucleoprotein complexes also maintain the 
structural and functional integrity of telomeres.
3
 Telomeres resolve the replication problem at the 
end of linear chromosomes, by involving a specialized enzyme called telomerase. After each round 
of DNA replication, all telomeric repeats are lost and the DNA risks losing coding sequences with 
subsequent rounds. Therefore, a telomerase attaches to the end of a chromosome and adds the 
complementary RNA bases to the 3’ end of the DNA. Telomerase enables the mammalian cells to 
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differentiate between the normal chromosomal ends and the double–stranded DNA breaks, which in 
turn prevents the initiation of DNA damage repair or apoptotic pathways.
3, 4
 Therefore, a telomere 
forms a physical cap over the end of linear chromosomes which is entirely vital for maintaining the 
genetic repository in eukaryotic cells. 
1.1.1.  Biological Background of G-quadruplex Stabilizing Agents 
The secondary structure of DNA is a standard right-handed double helical conformation (B-
DNA). However, biophysical techniques such as X-ray crystallography and circular dichroism have 
shown that DNA can assume secondary structures other than the standard B-form. These include 
cruciforms, ZDNA (a left-handed double helical conformation) and G–quadruplexes, depending 
upon the specific DNA sequence motifs and the interaction of DNA with various proteins.
5, 6 
The G-
quadruplex structures or G-quartets (G4) were first observed in 1910 by Bang,
7
 who noted that 
when a concentrated solution of guanylic acid is cooled down, it forms a transparent gel in an 
aqueous solution, suggesting that guanine-rich DNA sequences can form stable higher-order 
structures. The absolute structure and arrangement of these G-quadruplexes was determined in 1962 
when Gellert and Davies found that tetrameric guanine bases form a novel structure by internal 
hydrogen bonding (called the Hoogsteen bonds).
8
 Recent evidence shows that G-quadruplex 
structures play significant roles in the regulation of various steps of gene expression including the 
initiation of transcription, the alternate splicing of mRNA, the modulation of translation, and the 
synthesis of microRNAs.
9
 The in vivo role of G-quadruplex structures was first elucidated by 
studying the transcriptional regulation of a myelocytomatosis viral oncogene (v-myc) of the avian 
myelocytomatosis virus.
9
 The transcription of this oncogene is tightly controlled by a set of four 
promoters (P1-P4), nuclease hypersensitivity elements, and various transcription start sites.
10
 One of 
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the nuclease hypersensitivity elements, NHE III1, located upstream of the P1 promoter, contributes 
largely to the transcription regulation. This region contains five consecutive sets of G-rich 
sequences (G/A)G(G/A)AGGGGT, which are thought to arrange and stabilize the G-quadruplex 
structure, and possibly inhibit the transcription of this gene.
10, 11
   
1.1.2.  G-quadruplex DNA 
The G-quadruplex (G4) structures are formed in genomic regions that are rich in guanine 
nucleotides. These G-rich sequences are mostly present in telomeres, near transcriptional start sites, 
and at double-stranded break sites for mitosis and meiosis. Telomeres consist of a square planar 
arrangement of four-guanine molecules attached to each other through Hoogsteen hydrogen 
bonding. These G-quadruplexes stack over each other just like the nucleotide bases stack over each 
other in double-stranded DNA, forming a three-dimensional complex termed G4 structure, (Figure 
1).
12
 Between the stacked G-quadruplexes, there may be intervening sequences that are not involved 
in G4 structure formation, and thereby persist as small single-stranded loops varying from one to 
seven nucleotides in length.
12
 The stability of the G4 structure is achieved by the presence of 
monovalent cations, particularly K
+
 (and less frequently NH4
+
 and Na
+
), between the stacked G-
quadruplexes. The monovalent cation helps to decrease the electrostatic repulsion between the 
guanine and carbonyl oxygen atoms in the adjacent layers.
13, 14
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Figure 1: (A) Formation of a G-quartet in a square planar arrangement after hydrogen bonding 
among guanine molecules, and (B) Stacking of G-quartets to form a G4 structure.
6
 
 
 
1.1.3.  Telomere and Telomerase in Cancer 
Telomeres are the DNA sequences that are found at the end of linear chromosomes. In the 
late 1980s it was found that the biology of telomeres was altered in the process of tumorigenesis. 
15
 
Subsequent studies have shown that the telomerase enzyme is actively present in human malignant 
hematopoietic cells and in human ovarian carcinoma.
16, 17 
The PCR-based technique, Telomeric 
Repeat Addition Protocol (TRAP), enabled the amplification and detection of the telomerase-
elongated 3’-overhang of the leading strand. Using this technique, it was found that 82%–95% of 
breast cancers and 80% - 85% of other human tumors show telomerase activity.
30
 Telomerase in 
cancer cells was found to be actively involved in the maintenance of the short length of telomeres, 
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thus, providing genetic stability and saving the cell from apoptosis.
19
 Histological studies of 
malignant cells of various human tissues show that telomerase activity is due to the over-expression 
of the hTERT domain. Cancer cells attain replicative immortality by being able to maintain the 
length of telomeres by the over-expression of hTERT.
20
 As a result of the association of telomerase 
with human cancers, telomerase has been tested in hundreds of studies as a potential sensitive 
biomarker for screening, early detection, prognosis, and the monitoring of the pathophysiology of 
the residual disease.
21
 
 
1.1.4.  G-quadruplex Binding Ligands as Potential Telomerase 
Inhibitors 
Telomeric G-quadruplex stabilizers (ligands) have been recognized as a potential new 
approach for anticancer therapeutic agents for their inhibition of telomerase activity.
22
 This 
recognition has led to an interest in G-quadruplex structures as a potential anticancer drug target 
that hinges on the ability to design and develop a large number of small molecules that selectively 
bind and stabilize the telomeric G-quadruplexes, thus blocking the action of the telomerase or 
deactivating G-quadruplex–related gene expression.23, 24 The common features shared by many of 
the G-quadruplex ligands are a flat or planar aromatic ring structure and, in most cases, cationic side 
chains with sizes corresponding to G-quadruplexes.
25, 26
 The ligand model interacts mainly with the 
terminal G-quadruplexes through a potential - stacking at the end of G-quadruplexes and 
electrostatic interactions (or hydrogen bonding with G-quadruplexes).
27, 28
 The most famous and 
potent compound discovered so far is the metabolite telomestatin,
27, 29
 a macrocyclic polyoxazole 
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natural compound that has proven to be a highly selective G-quadruplex stabilizer. The compound 
was identified as a particularly useful probe of the telomerase function as a result of its valuable 
biological properties. 
In the 1990s, many natural products containing oxazole and thiazole were isolated from marine 
organisms 
30, 31
 that had attractive biological activities toward G-quadruplex stabilization. 
Although a diverse array of G–quadruplex-interactive ligands have been prepared using various 
synthetic processes; most researchers have screened natural products in order to identify new G–
quadruplex stabilizers. Of the G–quadruplex interactive agents identified to date, many have 
significant selectively in terms of G–quadruplex structures with telomerase inhibition. This 
selectivity has led some researchers to search for natural products that inhibit telomerase activity. 
Among these, telomestatin, a 24-member macrocycle consisting of the linkage of two 
methyloxazoles, five oxazoles, and one thiazoline ring (Figure 2), has been identified and 
characterized by Shin-Ya and co-workers.
32
 Telomestatin was isolated from Streptomyces 
anulatus 3533-SV4 and is one of the most potent inhibitory agents with low nanomolar activity 
reported against telomerase (IC50 = 5 nM).
33, 34, 35
 Hurlely and co-workers experimentally proved 
that telomestatin resembles G-tetrads, which selectively facilitate the formation or stabilization 
of intramolcular G-quadruplexes produced from 3’ telomeric overhangs of human 
chromosomes.
27
 Studies have indicated that the proposed mode of action of telomestatin which 
contains planar aromatic rings,
36, 37
 involves the interaction of telomestatin with human telomeric 
G-quadruplex by stacking on the terminal G-tetrads.
28
 The stabilization of telomeric G-
quadruplex structures with telomestatin as a ligand has reportedly inhibited the telomerase 
activity that elongates the telomere sequences.
38
 Telomestatin is involved in various biological 
activities. For instance, it induces prompt cell death selectively, killing cancer cells but not 
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killing cells in normal fibroblasts. It was reported that telomestatin does not cause a significant 
weakening of the telomere in either cancer or noncancerous cells under short time conditions, 
and it induces the loss of single–-stranded telomeric 3’ overhangs.39, 40, 41 In addition, the 
telomere shortens with the G–quadruplex formation, and telomestatin induces the dissociation of 
TRF2, which is the telomere–binding protein that is responsible for telomere stabilization42 and 
induce the expression of ribonuclease PO1 from telomere in cancer cells. Therefore, telomestatin 
induces apoptosis. 
The reasons behind these biological activities are due to the high affinity of telomestatin for 
intramolecular G-quadruplexes over the intermolecular G-quadruplex structures. Interestingly, 
telomestatin was found to have a > 70 fold selectivity for intramolecular G-quadruplex structures 
over duplex DNA.
43
 The selectivity of telomestatin between different G-quadruplex sequences and 
the binding affinity toward G-quadruplexes are rationalized by size and shape that are comparable 
with G-tetrads of G4 DNA.
44, 27
 However, the shape of telomestatin is not ideal because of the 
presence of a single thiazoline unit (sp
3 
carbon).
45
 Despite its superior properties and selectively, 
telomestatin is not available in great quantity. 
25
 Moreover, telomestatin has one major drawback: it 
is difficult to obtain.
26, 44
 The most effective method of obtaining telomestatin is by isolation from 
Streptomyces anulatus. Although telomestatin can be produced by bacterial fermentation, the yield 
is quite low because of the inefficient fermentation.
46, 47
 Several synthetic approaches have been 
unsuccessful,
31, 48, 49, 50
 a total synthesis of telomestatin has been described only in one patent,
51
 
(with the stereocenter of a thiazoline ring in an R configuration ).
52, 53
 However, the synthetic route 
of (R)-telomestatin is incompatible with industrial–scale production26 and even with the production 
of derivatives. Recently, the total synthesis of the (S)-isomer of telomestatin
54
 (Figure 2) was 
reported by the Takahashi group. It was found to be more potent and a stronger inhibitor than that 
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isolated from Streptomyces anulatus. Synthetic (S)-telomestatin was four times more active against 
telomerase. More significantly, since it has no hydrophilic functional groups, thus explaining the 
poor solubility in water.
26
 The poor solubility of telomestatin can seriously hinder its 
bioavailability, an important consideration when dealing with medical drug candidates. 
Despite the low availability of telomestatin, its noteworthy biological activities have 
motivated and inspired some researchers to synthesize and design telomestatin analogues that have 
improved features over telomestatin.
44, 55
 Telomestatin is difficult to synthesize and hard to formulate 
because it lacks water-solubilizing groups, such as hydroxyl or amine groups. Recently, several 
telomestatin derivatives have been reported as G-quadruplex stabilizers or binders. 
 
 
 
Figure 2:Structures of telomestatin (R)-1 and its enantiomer (S)-1.
54
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1.2.   An Alternative Approach to Prepare Synthetic Analogues of 
Telomestatin 
1.2.1.  Structure and Evaluation of Poly-oxazole Macrocycles as G-
Quadruplex Stabilizers 
Many research groups have undertaken the design of G-quadruplex ligands with the aim to 
stabilize telomeric G-quadruplexes. A series of macrocyclic hexaoxazole-type (6OTDs) and 
heptaoxazole-type (7OTDs) telomestatin derivatives containing various functional groups have 
been synthesized and evaluated. These novel telomestatin derivatives possess a characteristic planar 
aromatic core structure with a size corresponding to the G-tetrad to promote an end -stacking with 
the G-quadruplex structure.
56
 Many of these G-quadruplex ligands contain cationic moieties (basic 
side chains) to cause an attractive interaction with the anionic backbone (phosphate backbone) and 
the grooves of the telomeric G4.
57
 All of these compounds exhibit a high degree of specificity 
towards the interaction with G-quadruplex structures,
58
 and inhibit both human telomerase activities 
and telomeric DNA-binding proteins by preventing their access to the telomere.
59,60
 
1.2.2. Macrocyclic Hexaoxazoles (6OTDs) 
The first derivative of macrocyclic hexaoxazoles was hexaoxazole HXDV, 2, a 24-
membered macrocycle containing 6 oxazole and 2 valine side chain (Figure 3). Rice and co-
workers
61
 determined that HXDV binds and thermally stabilizes the telomeric G-quadruplexes in 
the presence of K
+ 
ions, but has no ability to stabilize the duplex or triplex form of DNA. The high 
selectivity of HXDV towards G-quadruplexes appears to be related to its structure which is suited 
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for binding to G-quadruplexes. Its scaffold is derived from a particular telomestatin-like concave 
shape, which has 2-planar trioxazole moieties linked by a valine residue on the same face of the 
cycle.
45
 Thus, its structure facilitates -stacking interactions with quartets. Current studies have 
indicated that the binding mode of this molecule to G-quadruplexes is via a “terminal capping” 
interaction with a stoichiometry of 2:1 between HXDV and [d (T2AG3)]4 repeats.
62,55
 Unlike 
HXDV, macrocycle 3, containing four oxazole rings with alternative tetra-isopropyl substitutions 
(Figure 3), did not stabilize G-quadruplex DNA and was not cytotoxic. HXDV has a moderate level 
of cytotoxicity towards human lymphoblastomas and murine leukemias with an IC50 value of 0.4 
M. Since HXDV is not very soluble in aqueous solution, the side chain of HXDV has been 
modified in an attempt to prepare derivatives with improved solubility. 
A related derivative, 4, was synthesized using a ring-closing metathesis approach. This 
involved replacing one of the valine linkages in HXDV with a propenyl group.
63
 The compound 4 
displayed a high cytotoxic potency against five different tumor cell lines, having an IC50 of 25 M. 
It also exhibited a preference for G-quadruplex structures over any other form of DNA, indicating 
that the amide bonds are not important for enhancing the activity in these structures. Bistrioxazole 
acetate (5) was synthesized and its biological activity has been tested.
64
 It exhibits telomerase 
inhibitory activity with an IC50 of 2 M. The asymmetric centers in the macrocyclic bisamide-
related telomestatin derivatives are thought to play an important role in their interaction with G-
quartets. 
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Figure 3:Structures of HXDV and related uncharged telomestatin derivatives.
25
 
 
Nagaswa and co-workers 
65 
reported the synthesis of a set of telomestatin derivatives, L2H2-
6OTD dimers (Figure 4), which have macrocyclic hexaoxazole structures. The dimers 6, 7 and 8 
were connected by linkers of 3 different lengths (9-11). The ability of these compounds to interact 
with telomeric DNA was compared to that of corresponding hexaoxazole monomers. The optimum 
interaction with the telomeric G4 was obtained with dimer 7 because its scaffold is able to span the 
thickness of the G-quadruplex DNA. Thus, dimer 7 had a ten-fold higher selectivity for interaction 
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with telomeric DNA when compared to the corresponding monomer. Unexpectedly, 7 has a lower 
affinity compared to the corresponding monomer. Therefore, 7 exhibits potent G-quadruplex 
stabilizing activity. Since it interacts with the telomeric G-quadruplex DNA forming a 1:1 complex 
(Figure 5), the two macrocyclic moieties in 7 are expected to interact as terminal caps of outer G-
tetrads on the same quadruplex, whereas the ratio of the corresponding monomer is 2:1 similar to 
that found for telomestatin and HXDV.
65
 
 
 
 
 
Figure 4: Structure of hexaoxazole macrocyclic L2H2-(6OTD) dimers.
65
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Figure 5: The binding mode of the 6OTD dimers.
57
 
 
Although telomestatin-like molecules that consist of the macrocyclic oxazole scaffold 
interact and stabilize the G-quadruplex structure, they exhibit limited aqueous solubility. It was 
suggested that the replacement of one or both isopropyl groups of HXDV (2) with cationic side 
chains would help improve the aqueous solubility of the compounds, and enhance the affinity and 
selectivity for specific G-quadruplex sequences, especially because these derivatives have a planar 
core. This strategy would be expected to provide strong, selective G4 binders with the cationic 
functional groups that would directly bind to G-quadruplex grooves by forming salt bridges with the 
phosphate backbone. 
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A series of the symmetrical macrocyclic hexaoxazole analogues of HXDV 2 with cationic 
side chain appendages was synthesized and evaluated (Figure 6). Rice and co-workers investigated 
the ability of L2H2-6OTD-HXDL, diaminobuty(lysyl)hexaoxazole 9, to stabilize telomeric DNA, 
and they found that 9 is the most promising; it provides the greatest ability to stabilize the G-
quadruplex structure as compared to HXDV 2 and related analogues that contain only one amino 
group.
44
 Compound 9 was found to form an anti-parallel-type G4 structure when it interacted with 
telo 24 or longer telomeric DNA (i.e., telo 48, 72, and 96) in an end-stacking mode using two 
molecules of HXDL.
66
 The reason behind the high solubility of HXDV 2 is that it has water-soluble 
functional groups on both of the terminal amino acid groups, which makes it charged at 
physiological pH. Apart from -stacking (planarity of trioxazole) and electrostatic interactions 
(hydrogen bonds with phosphate backbone), such functionality may also impart HXDL 9 the 
efficiency of enhancing the binding to G-quadruplex-DNA. 
Compound 10 is a G-quadruplex binder which has a guanidine-containing side chain 
hexaoxazole macrocycle (6OTDs).
58
 Compound 10, reported by Nagasawa and co-workers,
56
 
exhibited a superior ability to inhibit telomerase activity, and a preference toward anti-parallel 
telomeric G4 structures over the parallel one, while L2A2-6OTD (N-acetylaminopropyl) 11 did not. 
Both HXDL (9) and L2G2-6OTD (10), which contain positively charged functional groups, showed 
significant induction of the intramolecular quadruplex structure in the absence of metal ions.
57
 Rice 
and co-workers have studied the variation of side chains in a series of hexaoxazole macrocycle 
ligands. Ligand 12, [(dimethyl)amino]ethyl-isopropylhexaoxazole, displayed a high degree of 
specificity towards G-quadruplex stabilization, as observed from the UV melting profiles. The 
cytotoxic activity of 12 was greater than that of HXDV, with the IC50 range between 0.025 and 3.5 
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M. Ligand 12 was evaluated in vivo as a potential antitumor agent against human tumor xenografts 
in mice.
67 
 
 
 
Figure 6: Structures of hexaoxazole macrocyclic amine-based G-quadruplex ligands with 
cationic side chains. 
44,58,67
 
 
The hexaoxazole-based macrocycle-containing methyl oxazoles, L2A2-6M(2)OTD 13 and 
L2A2-6M(4)OTD 14, were recently reported by Nagasawa and co-workers (Figure 7). They found 
14 to be a more effective stabilizer than 13. Thus, it was revealed that the ligand-induced 
stabilization of G-quadruplex DNA increased by an incremental number of “methyl oxazole” 
moieties in the macrocyclic hexaoxazole.
68
 Y2H2-6OTD 15, a macrocyclic hexaoxazole with a L-
tyrosyl side chain, exhibited a significant improvement in stabilizing telo 24. This might be due to 
the presence of OH groups, which interact with the phosphate backbone.
56
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Figure 7: Structures of substituted hexaoxazole macrocyclic G-quadruplex ligands.
68
 
 
1.2.3. Macrocyclic Heptaoxazoles (7OTDs) 
Recently, Takayuki and co-workers have designed a series of heptaoxazole macrocycles 
that have planar skeletons resembling telomestatin. They anticipated that adding one more 
oxazole moiety into the corresponding hexaoxazole scaffold would increase the planarity of the 
macrocyclic structure. Thus, it was expected that the heptaoxazole macrocycles interact strongly 
and more efficiently with telomeric G-quadruplex DNA through – stacking interactions, 
regardless of the functional group of the side chain. The planar amine-linked heptaoxazole 
analogues (L1H1-7OTD) 16 (Figure 8), with positively charged side chains, were found to be 
more favorable G-quadruplex binders than the corresponding hexaoxazole. Compound 16 
appears to be a powerful scaffold for stabilizing telomeric antiparallel G-quadruplexes. The 
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amino group in the heptaoxazole scaffold has a significant role in stabilizing telomeric G-
quadruplexes due to the protonation of this group under physiological conditions. Compound 16 
exhibited potent telomerase-inhibitory activity.
69
 
The novel fluorescently-labeled G-quadruplex ligand L1BOD-7OTD 17 has been developed 
by attaching a BODIPY (4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene) moiety to the side chain. This 
was used to visualize the G-quadruplex structure in cells. Moreover, it can selectively induce the 
formation of intramolecular G-quadruplex from some G-quadruplex-forming oligonucleotides 
(GFOs).
70
 
 
 
Figure 8: Structures of telomestatin–related heptaoxazole macrocycles.69 
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Takayuki and his co-workers studied the effects of side chain variation in (R)-heptaoxazole 
macrocyclic analogues of telomestatin, and have evaluated the telomerase-inhibitory activity. They 
synthesized three different methyloxazoles moieties (R) 18a-c and one with a bromooxazole moiety 
19 (Figure 9).
53
 They found that substitution of the oxazole rings in heptaoxazole macrocycles, such 
as a methyl group or a bromine atom, have no significant effect on telomerase inhibitory activity or 
on the interaction with the G-quadruplex backbone, although it was reported that the induction and 
stabilization of G-quadruplexes increased with an incremental number of methyl oxazole moieties 
in the hexaoxazole.
68
 Based on their observations, the planarity of heptaoxazole macrocycles could 
allow the ligands to interact whit the telomeric G-quadruplex structure by – stacking interactions 
regardless of the character of side-chain groups. Furthermore, the various aromatic rings introduced 
in 20a–f on the oxazole rings had no effect on the telomerase inhibitory activity suggesting that the 
side chain do not interact with the telomeric G-quadruplex. In addition, the authors synthesized 
three amine-linked heptaoxazole macrocyclic analogues 21a–c (Figure10) and examined their 
activity against telomerase. The amine-linked heptaoxazole macrocycle 21a proved to be as potent 
as telomestatin, while 21b–c were slightly less potent. Side-chain length was found to enhance the 
potencies of the ligands. It is worth noting that the positively charged amine-linker favors 
electrostatic interactions. Such functionality could reach the phosphate groups of quadruplex 
grooves to stabilize the G-quadruplex DNA structure. 
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Figure 9: Structures of substituted heptaoxazole macrocyclic G-quadruplex ligands.
53
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Figure 10: Structures of amine-linked heptaoxazole macrocyclic based G-quadruplex ligands.
53
 
 
1.2.4. Synthesis of Macrocyclic Hexaoxazole Ligands (6OTD) 
The synthesis of telomestatin-related hexaoxazoles was achieved by Shin-ya and co-workers
64
 
using a convergent synthesis. The compound was built from two segments of trioxazole 25  
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(Scheme 1), which was the key synthetic intermediate in the synthesis for macrocyclic 
hexaoxazoles. The synthesis of the 25 began by coupling L-serine methylester bearing different 
protecting groups. The coupling was done using 1-[3-(diethylamino)propyl]-3-ethylcarbodiimide 
hydrochloride (EDCl). The resulting dipeptide 22 (Scheme 1) was subjected to a 2-step reaction 
with the fluorinating agent diethylaminosulfur trifluoride (DAST) to give an oxazoline, followed 
by an oxidation using bromotrichloromethane BrCCl3 /DBU to yield the oxazole 23. The 
resulting compound 23 was deprotected and dimerised to give 24. Compound 25, was generated 
by a cyclodehydration reaction of 24 with DAST followed by oxazole formation with 
DBU/BrCCl3 to give trioxazole, which represents half of the target compound. Macrocyclic 
bisamide 27 was synthesized by dimerization of trioxazole 25, giving the linear hexaoxazole 26 
(Scheme 2), followed by deprotection of 26 and a macrocyclization performed under dilute 
conditions (1 mM) using N,N-bis(2-oxo-3-oxazolidinyl)phophinic chloride(BOPCl) and 
diisopropylethylamine in DCM-DMF. A final deprotection step allowed for the installation of 
various functional groups on the side chain, e.g., an acetyl group (OAc), to obtain compound 27. 
Rice and co-workers 
61
 synthesized HXDV 2 (Figure 3) by following a similar strategy. Shin-ya 
developed the 6OTD that has an amine-containing side chain instead of alcohols. 
58
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Scheme 1: Synthesis of the trioxazole (25).
64 
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Scheme 2: Synthesis of hexaoxazoles (27).
64
 
 
1.2.5. Synthesis of Macrocyclic Heptaoxazole ligands (7OTD) 
Shin and co-workers proceeded to synthesize 7OTDs after the synthesis of telomestatin and 
related hexaoxazoles.
69
 The total synthesis of heptaoxazoles (Scheme 3) is similar to that used for 
hexaoxazoles. The only difference between them is the use of two different trioxazoles that afforded 
a macrocycle with orthogonally protected side chains. The trioxazole 28 was prepared as previously 
reported.
64, 58
 Briefly, coupling of the two of trioxazoles 28, which was prepared in 6 steps, yielded 
the macrocyclic bisamide 29. Compound 29 has two orthogonally protected side chains, of which 
TBS was deprotected to furnish the alcohol, and then converted into the enamide 30 by mesylation 
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and DBU treatment. By reacting with N-bromosuccinimide (NBS) and Cs2CO3 in acetonitrile at a 
high temperature (65 °C), 30 was transformed into 31. This unconventional method was likely 
chosen due to the problem encountered when using the typical reagent DAST. Compound 30 was 
problematic because of the strained structure of the -hydroxyamide moiety.44, 61, 62, 71, 52 
 
 
Scheme 3: Synthesis of heptaoxazoles (31).
69
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1.3.   Development of a Synthetic Methodology for Poly-oxazole 
Macrocycles  
Cyclic peptides that are derived from natural products are present in every living cell, and 
carry out a variety of biological activities. They work as hormones, enzymes, receptors, as well as 
antibacterial, antiviral, immunosuppressor, and anticancer agents.
72,73
 The isolation of these 
naturally occurring cyclic peptides required long incubation times (fermentation or degradation), 
with such methods often providing low quantities of related analogues.
74,75
 Despite the difficulties 
of scaling up these products, scientists have been synthesizing them in laboratories in great 
quantities, as they are needed for the study of their biological activities. 
 
1.3.1. Common Methods of Oxazole Synthesis 
Hantzsch discovered oxazoles in 1887.
76, 77
 Oxazoles are widespread, occurring in many 
natural products and their heterocyclic oxazole derivatives have been synthesized and have been 
reviewed extensively.
78, 79, 80
 Because these compounds are known to display a wide range of 
biological activities, a number of methods have been developed for their efficient construction. By 
far the most common type of oxazole found in natural products are the 2,4-disubstituted oxazoles. 
There are two general pathways to generate the 2,4-disubstituted oxazoles from hydroxyamides: (A) 
by dehydrative cyclization affording an oxazoline followed by oxidation to obtain the 
corresponding, oxazole, or (B) by oxidation to a 1,4-dicarbonyl species followed by 
cyclodehydration to give the oxazole (Scheme 4).  
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Scheme 4: Possible routes in the synthesis of 2,4-disubstituted oxazoles from hydroxyamides.  
 
 Researchers have therefore sought to develop an efficient synthesis based on these types of 
reactions. Initially, the formation of oxazoline could only be achieved by the activation of the 
hydroxyamide function in a manner that would induce the cyclization without any racemization at 
the chiral centers. There are many ways to activate the hydroxyamide prior to cyclization such as 
the Mitsunobu reaction,
81,82
 using triphenylphosphine, carbontetrachloride (tetrachloromethane) and 
DIPEA,
83
 or the more commonly encountered Burgess regent,
85
 and DAST.
85, 86, 87
 The most 
commonly used route toward oxazole synthesis is the cyclization–oxidation pathway. This approach 
is utilized in this work, and discussed in the following sections.  
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Wipf and co-workers introduced methyl N-(triethylammoniumsulfonyl)carbamate, also 
known as Burgess reagent 36, in the preparation of natural products containing oxazoles.
88
 The 
Burgess reagent acts as a mild and selective dehydrating agent, which is often used for the 
cyclodehydration of hydroxyl amides to afford the corresponding 5–membered heterocycles. The 
mechanism is outlined in Scheme 5. The hydroxyl group attacks the sulfonyl group of the Burgess 
reagent to form a sulfonyl ester, which can be easily transformed into oxazoline by the inversion of 
the configuration at the carbon (–position) bearing the sulfamate as the leaving group or 
intramolecular cyclization (SN2 substitution). According to the literature, the Burgess reagent allows 
the successful suppression of the epimerization at the -carbon compared to other cyclization 
methods.
89
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Scheme 5:  The proposed mechanism of oxazoline formation with Burgess reagent. 
 
In a typical Burgess-mediated cyclization, the starting material in dry THF reacts with 1 
equiv. of the Burgess reagent and is refluxed under a nitrogen atmosphere at 70
o 
C. The use of the 
Burgess reagent has been demonstrated by Pattanden and Freeman’s in the total synthesis of 38 as 
the final step for cyclodehydration (Figure 11).
90
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Figure 11:  Conversion of -hydroxyamide into oxazoline by Burgess reagent.90 
 
Alternatively, the conversion of -hydroxyamide into the corresponding oxazoline proceeds 
more efficiently when DAST (diethylaminosulfur trifluoride) was employed in the 
cyclodehydration step.
87
 DAST (39) is a nucleophilic fluorinating agent used for the conversion of 
alcohol to the corresponding alkyl fluorides. The oxazoline formation involves the nucleophilic 
displacement of fluoride from highly electrophilic sulfur atoms in DAST.  The alcohol oxygen atom 
of the -hydroxyamide is converted into an activated species with a higher leaving group 
capacity.
91, 92
 The carbonyl group or amide oxygen atom is a good nucleophile that causes the 
intramolecular attack of the activated hydroxyl group (inversion of configuration) which is faster 
than the substitution by the fluoride, thereby producing the corresponding oxazoline (Scheme 6). 
An important safety consideration associated with the use of DAST in the laboratory is the 
shock and thermal instability of pure DAST.
93
 Therefore, the oxazoline formation with DAST must 
proceed at -78°C to avoid local overheating and the risk of an explosion.  
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Scheme 6:  Mechanism of the DAST-mediated cyclodehydration of -hydroxyamide into 
oxazoline.  
 
The oxidation of oxazoline has been developed extensively to proceed by either an addition–
elimination sequence or a radical pathway. In either case, the transformation requires the need for 
an enolizable group at the 4–position to obtain the oxazole with a good yield. Many methods have 
been reported for the oxidation of oxazoline to oxazoles, including (1) nickel peroxide in refluxing 
benzene,
94
 (2) NBS with either benzyl peroxide or light,
95
 (3) the Kharasch–Sosnovsky reaction,96, 
97
 and (4) bromotrichloromethane and 1,8-diazabicycloundec-7-ene (DBU).
 98
 The disadvantage of 
the first and second methods is that the yield of oxidized products rarely exceeds 40-50%,
94 
and that 
-bromination side products are formed when using NBS, with either benzyl peroxide or light.95 
Both of the two remaining methods have been investigated for the synthesis of 2-substituted-4-
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carbomethoxy oxazole and thiazole.
96, 97, 98
 The Kharasch–Sosnovsky reaction was the first chosen 
to be optimal for the oxidation to take place.
96, 97
 
A cocktail of copper (II) acetate, copper (I) bromide, and tert-butyl perbenzoate was 
successfully applied to the oxidation of oxazoline and thiazoline. Scheme 7 shows the proposed 
mechanism of the copper-ion catalyzed radical reaction. The proposed process involves either of 
two mechanisms. In both there is the generation of a radical at the oxazoline by the peroxyester 
radical, catalyzed by Cu
+
, followed by the oxidation of the radical to a carbocation by Cu
2+
 at the 4 
or 5 position of the oxazoline ring.  In the mechanistic pathway A, the resulting radical intermediate 
at the -carbon is oxidized to form the intermediate cation 40a.  This carbocation is rapidly 
neutralized by a rapid elimination of a proton to provide the oxazole. On the other hand, in path B, 
the radical is oxidized to the intermediate 40b, which provides the oxazole after elimination of a 
proton at the -carbon to neutralize the positive charge.95 
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Scheme 7:  The proposed mechanism for the oxidation of oxazoline to oxazole.  
 
The addition-elimination of the bromotrichloromethane-DBU oxidation reagent is used for 
the selective oxidation of the oxazoline into an oxazole.
98
 This oxidation using BrCCl3–DBU 
proceeds through a C4-bromooxazoline intermediate which readily eliminates HBr to afford the 
oxazole (Scheme 8).
86, 87, 99 
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Hennoxazole A 46 was isolated from the chloroform extracts of the marine sponge, 
polyfibrospongia sp. and it is found to exhibit potent antiviral activity against herpes simplex virus 
(HSV-1). William successfully applied the cyclodehydration-oxidation protocol to the synthesis of 
2,4–disubstituted bisoxazole 45 in his total synthesis of hennoxazole A 46 using DAST and the 
DBU–BrCCl3 regent.
100
 The total synthesis of 46 involved the treatment of 41 with DAST at -78
 o 
C 
that first led to oxazoline 42, followed by mild oxidation with the BrCCl3–DBU reagent to allow the 
rapid dehydration and formation of the oxazole 43 in good yield. The ester was saponified to give 
the corresponding acid precursor, which was then coupled with serine methylester to obtain an 
amide 44. The latter was subjected again to the cyclodehydration-oxidation strategy and yielded the 
bis-oxazole core 45 of hennoxazole A 46 (Scheme 9).  
 
 
Scheme 8: The addition–elimination mechanism of the oxidation of oxazoline to oxazole by 
DBU-BrCCl3. 
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Scheme 9: Total synthesis of hennoxazole A using cyclodehydration-oxidation protocol.
100
 
Reagent: (a) DAST (1eq), DCM, -78°C, 1h; (b) K2CO3, -78°C- 0°C; (c) BrCCl3, DBU; (d) 
LiOH, THF, H2O; (e) iBuOCOCl, Et3N, serine methylester.HCl, DCM, -20°C.  
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1.3.2. Macrocyclization Strategies for Cyclic Peptides 
Cyclic peptides have several advantages as therapeutic agents, such as high resistance to 
degradation and elimination, and an increased affinity towards a molecular target.
101
 The 
macrocyclization is one key step in the synthesis of cyclic peptides and is a useful strategy to reduce 
their flexibility. In general, there are four ways to constrain a peptide into a macrocycle: head-to-tail 
(C-terminus to N-terminus), head-to-side chain, side chain-to-tail, or side chain-to-side chain 
(Figure 12). Researchers have used all of these methods to form a variety of macrocycles.
102
  
 
 
 
Figure 12: The four different ways of peptide cyclization.
102
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An example of the side chain-to-side chain macrocyclization is the synthesis of a cyclic 
peptide that interrupts the Tat-RNA interaction for the inhibition of HIV-gene expression.
103
 To 
cyclize a peptide via this strategy, the linear precursor was anchored to a solid support and the 
peptide bond (amide bond) was formed between the side chains of L-glutamic acid and L-lysine 
(Figure 13). 
 
 
 
 
 
 
 
Figure 13:  Synthesis of a cyclic peptide via side chain-to-side chain cyclization.
103
 
 
Aldrich and co-workers
104
 synthesized dynorphin A analogs using the head-to-side chain 
cyclization. Dyn A is an endogenous opioid peptide that is produced in many parts of the brain, and 
plays a role in the modulation of pain responses. The Dyn A analog was synthesized through the 
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formation of a lactam bond in which the N-terminus was attached to the glutamic acid side chain 
(Figure 14).
105
 
 
 
 
Figure 14:  Side chain-to-tail cyclization of cyclic dynorphin A.
105 
 
 
Williams and co-workers
106
 used the head-to-side chain macrocyclization strategy in 
synthesizing a class of thiolactone cyclic pentapeptides that are responsible for inhibiting 
staphylococcal virulence. The cyclization to generate the staphylococcal virulence inhibitor peptide 
involved a thiolactone linkage formation via a condensation of the cysteine side chain to the C-
terminal carboxylic acid (Figure 15). 
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Figure 15: Head-to-side chain cyclization to generate the thiolactone linkage in a staphylococcal 
virulence inhibitor.
106
 
 
Head-to-tail macrocyclization is a convenient and efficient methodology for cyclizing a 
peptide in solution. This method has been successfully applied in synthesizing long peptides (up to 
20 residues), although the factor that governs the success or failure of a head-to-tail peptide 
macrocyclization is the conformation of the linear peptide precursor in the solution. One of the 
notable examples of the use of head-to-tail macrocyclization is the synthesis of the cyclic 
depsipeptide Halipeptin A 
107
. Halipeptin A has been isolated from the marine sponge Haliclona 
sp., and exhibits promising anti-inflammatory activity in vivo.
108
 The cyclization of Halipeptin A 
was done by the Hamada group, where the macrocyclization was achieved through peptide coupling 
at the N-MeOH-IIe/ Ala site (Figure 16). 
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Figure 16: Head-to-tail cyclization in the synthesis of halipeptin A.
107
  
 
1.3.3. Conformational Elements to Assist the Cyclization  
The success of macrocyclization depends on the ability of the linear precursor to prearrange 
its two reactive ends in close proximity to each other.
102
 Such prearrangement provides an efficient 
macrocyclization with fewer by-products from intermolecular processes. Helping to bring the two 
reactive ends of a peptide into close spatial proximity involves examining the secondary protein 
structure, and introducing turns into the peptide sequences. 
The incorporation of L- and D-stereochemistry affects the orientation of linear peptides 
because these variations are suited to induce -turns. When a peptide sequence consists of only all 
L- or D-amino acids, the cyclization is usually difficult or impossible because the -turns are not 
present.
102
 Kessler and co-workers have documented that N-methylamine acids and prolines play a 
role as -turn-inducing elements to position the linear peptide in an orientation that facilitates the 
cyclization.
109 
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1.4. Structural Features of Pseudo Cyclic Peptides 
Studies on the configuration of azole-based marine cyclic peptides, both in solution and 
in the solid state, have provided insight into the factors that may affect the reactivities and the 
biological function of these unique secondary metabolites. The structure of westiellamide and its 
analogues has been investigated using X-ray diffraction and DFT- based molecular modeling. 
The structure of cyclic pseudo-peptides and their analogues depends on the configuration (R* vs 
S*) of the amino acid residues that connect to the macrocycles. The flexibility of macrocycles 
depends on the azole moieties. The structure of the macrocycles becomes relatively rigid due to 
the presence of the macrocyclic ring which fixes the position of the five ring atoms of the azole 
moieties, a feature which reduces the number of possible conformers.
110 
 
Usually, all peptide NH protons are located in the interior of the ring structure, and the 
carbonyl groups point towards the outside of the macrocycles. In case of westiellamide (Figure 
17), the functional groups (L-valine side chain) face the same side of the molecule, and adopt 
pseudo-axial positions. The heterocyclic rings of oxazole- or oxazoline-based pseudo cyclic 
peptides are almost coplanar, whereas the incorporation of thiazole and imidazole lead to a cone-
like structure.
111
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Figure 17: The chemical structures of the natural cyclic pseudo hexapeptide westiellamide and 
the cyclic pseudo hexapeptide H3L
1-3
.
110 
 
Haberhauer and co-workers used DFT to determine the structure of the cyclic peptides. 
The dihedral angle,  [Namide-C-Cazole-X], can be used to express the extent of deviations from 
planarity ( = 180 in case of planarity) (Figure 18). The authors showed that  depends on the 
azole system, and on the size of the amino acid side chains.
110
 
 
Figure 18: Nomenclature of heterocyclic building blocks of macrocycles. 
 
!
! 8!
 
Usually, all of the protons from the amide bonds point towards the center of the 
macrocycle whereas the carbonyl groups point towards the outside of the macrocyclic 
peptide. In addition, the amino acid side chains adopt axial positions. In the case where 
all the amino acid residues that connect the heterocycles have identical configuration (L- 
or D-), all the amino acid residues face the same side of the macrocycle. On the other 
hand, if the cyclic pseudo-peptides are built up from D- and L-amino acids, the 
macrocyclic peptides can exhibit an alternating stereochemistry in the linkers like 
ascidiacyclamide. Furthermore, the incorporation of oxazoline rings produces an almost 
coplanar structure of the heterocyclic moieties of the macrocyclic peptides whereas those 
p ptides th t c tain oxazole would h ve a cone-l ke structure.
11
  
 
 
Figure 7: Nomenclature of the heterocyclic blocks of the macrocycle.
11 
 
1.2.4 Westiellamide  
Westiellamide is a cyclic pseudo-hexapeptide isolated from the ascidian Lissoclinum 
bistratum. As in the bigger 24-membered azacrown-8 macrocycles, westiellamide, an 18-
membered azacrown-6 macrocycle, is highly preorganized for metal complexation. This 
compound has three oxazoline rings that are connected by amide bonds in a preorganized 
arrangement (Figure 8).
13,14 
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They calculated the change in relative energy of reference systems with a chiral amino acid 
coupled to an azole moiety induced by a change of χ by using density functional theory (DFT). 
The obtained energy profiles of the imidazole and oxazole reference systems with a small methyl 
side chain (Figure 19, left) exhibit two minima between 0and 200. The minima of the 
imidazole system are at 90 and 150, and those of the oxazole system are at 60 and 170. 
However, the thiazole reference system with a small side chain has three energetically similar 
minima at 30, 80 and 160. From these observations, Haberhauer and co-workers suggested 
that thiazole-containing macrocycles are more flexible. The energy profiles change significantly 
when replacing the methyl group by the sterically more demanding tert-butyl group (Figure 19, 
right). As a consequence, the larger side groups increase the activation barrier for rotation around 
. The energy profile changes remarkably which leads to shifts in the minima in the profile 
especially between = 120- 200, which are caused by electronic and steric effects. Each energy 
profile has only one minimum in the 100 to 150 range. The distinctive minima are at 149, 
129, 104 for oxazole, thiazole, and imidazole tert-butyl reference system, respectively. The 
reason for this behavior is mainly of electronic nature (Natural Bond Orbital (NBO) analysis): 
the  (Cazole-Nhet)-orbital of an imidazole ring is of high energy and, accordingly, the -bond 
prefers to interact with the  (C-Namide)- orbital. The optimum interaction between these two 
orbitals is at an angle of 90, where the  (C-Namide)-orbital is oriented parallel to the  (Cazole-
Nhet)-orbital. In contrast, in the oxazole system, the  (Cazole-Nhet)-orbital is of low energy and 
therefore preferably interacts with the high energy (C-C)- and (C-H)-orbitals. This 
interaction has its optimum at an angle  of 180.110,112 
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Figure 19: DFT-calculated energy profiles of the oxazole-, imidazole-, and thiazole- reference 
systems, in relation to the dihedral angel .110 
 
In the case of cyclic pseudo octapeptides, the conformation is dependent on the 
configuration of the connecting amino acids and the system’s symmetry.113, 114 The symmetrical 
peptides, such as C2-symmetric ascidiacyclamide, adapts a “square or saddle-shaped” 
conformation (Figure 20, left), in which all nitrogen atoms point towards the interior of the 
macrocycle with alternating oxazoline and thiazole moieties located at each corner of the 
macrocycle.
115, 114
 On the other hand, patellamide D, takes on a “figure-of-eight” conformation 
(Figure 20, right), which is stabilized by two intramolecular hydrogen bonds, and by -stacking 
of its thiazole  rings 
116, 113
 hence, leading to a rotation of the oxazoline rings such that the 
nitrogen atoms face the outside of the macrocycle. 
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Figure 20: Conformation of the backbones of the cyclic octapeptides ascidiacyclamide (left) and 
patellamide (right) in solution.
113, 114
 
 
1.5.   Copper (II) Coordination of Cyclic Pseudo Peptide 
The described macrocycle conformations make the cyclic pseudo-peptides well suited for 
the binding of metal ions.
117, 118
 The 24-azacrown-8 (pseudooctapeptide) macrocycle of 
ascidiacyclamide, patellamides, and some of their synthetic analogues have been shown to be 
able to coordinate divalent metal ions such as Zn
2+ 
and Cu
2+
.
119, 117 b, 120 
 The circular dichroism 
spectra  of the mono- and dinuclear copper (II) complexes of patellamide D have been 
reported.
121, 122
 In addition, the potentially biologically relevant ability of the dinuclear copper 
(II) complex of ascidiacyclamide to form carbonato-bridged complexes, where the copper (II) 
ions are bridged by a carbonate anion and embedded into the saddle-shaped conformation, has 
been reported.
119
 As shown in Figure 21, the copper (II) ions are coordinated to three nitrogen 
atoms (donors), from two heterocycles and a deprotonated amide, and its coordination sphere is 
Square or saddle shaped  Figure of eight  
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completed by two water molecules. 
120, 122
 These metal peptide conjugates could be involved in 
activation and transport of CO2 in vivo. 
 
Figure 21: X-ray structure of the carbonato-bridged dinuclear copper(II) complex of 
ascidiacyclamide. Top view (left), side view (middle) and chemical structure (right).
 
(Color code: 
carbon = grey, sulfur = yellow, nitrogen = blue, oxygen = red).
119
 
 
 Wipf and co-workers
123, 124
 were the first to describe the synthesis and X-ray structure of 
an Ag4 cluster of the C3-symmetric cyclic peptide westiellamide, which provided clear evidence 
of binding of the westiellamide to metal ions. In addition, the authors observed weak interactions 
between westiellamide and other metal ions such as sodium (I), copper (I), iron (II), iron (III), 
mercury (II), gold (II), and zinc (II),
124
 and found evidence for a strong interaction of copper (II) 
with the westiellamide macrocycles.
125
 Comba and co-workers have revealed that after the 
addition of base to copper (II) westiellamide and its synthetic analogues, the cyclic pseudo 
hexapeptides readily from stable dinuclear copper (II) complexes.
126
 
In the complexes, each copper (II) is coordinated by three nitrogen atoms of the 
macrocycle, and its coordination sphere is completed by one or two solvent molecules. In 
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mononuclear and dinuclear copper (II) complexes, the Cu (II) is coordinated with two of the 
coordinating nitrogen atoms originating from the heterocycles (azole rings) and one nitrogen 
atom from a deprotonated amide group, thus forming a N het -N amide-N het binding motif. In order 
to complex copper (II), the nitrogen atoms of the binding site need to be deprotonated. The 
deprotonation is metal ion-assisted, hence acidifying the solution due to the protons being 
released upon the coordination of copper (II) and thus, the addition of a base is mandatory to 
achieve complete complexation.
125
  
 
H4pat
1
, a C4-symmetric macrocycle that has four identical methyl imidazole units connected via 
L-valine linkers, is a simple model system for natural cyclic pseudo peptides (Figure 22). The 
formation of a carbonato-bridged dinuclear Cu
2+
 complex, which has been demonstrated with 
patellamide D and ascidicyclamide, could not be observed experimentally in the H4pat
1
 because 
the combination of imidazole heterocycles with an alternating R* and S* configuration. The 
imidazole rings induce a rigidity in the system and the alternating configuration induces steric 
strain that seems to hamper the reaction with CO2 imidazole heterocycle.
127
 Copper (II) 
complexation of patellamide D was observed based on the electronic, CD and EPR spectral 
titrations. The sequence of the complexation reactions with Cu
2+ 
was similar to that observed 
with the dicopper (II) complex with ascidicyclamide.
119, 128
  
 
A general scheme of solution equilibria has been proposed after extensive studies with a 
series of the synthetic analogues H4pat
1
- H4pat
5 
(Scheme 10). It is interesting note that the Cu
2+ 
in H4pat
3 
is not coordinated to the usual N het-N amid-N het binding motif but to the outside of the 
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macrocyclic system by oxygen atoms of the amide bond. In addition, the outside coordination 
has a higher stability than the mono- or dinuclear complexes at low base concentrations. 
However, high concentrations of base enable the coordination of copper (II) in the “ normal” N 
het-N amid-N het binding motif, indicating that the addition of base increases the deprotonation the 
amide nitrogens. The mono-hydroxo-dicopper (II) complexes have two isomers, one with a 
terminal and one with a bridging hydroxide.  Upon addition of excess base and the exposure to 
air to the carbonato-bridged and diaqua complexes, there is one more species in equilibrium 
(referred to as the “pink species”) which has not been fully characterized yet. These species have 
been observed with H4pat
3
 and H4pat
2
, but not for H4pat
1
 and H4pat
ascA
.  
 
 
Figure 22: Structures of the patellamide model systems H4pat
1 
to H4pat
5
, and the 
ascidiacyclamide analogue H4L
ascA
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Scheme 10: Assumed copper (II) complexation equilibria of H4pat
1-5
.
129
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1.6. Objectives  
The objectives of the thesis are two-fold: 
1) To prepare the tetraoxazole-containing macrocyclic compound, 55. 
2) To determine the ability of the macrocycle to complex Cu(II) ions. 
Boc- solution and solid phase chemistry will be investigated as means to accomplish the 
formation of the oxazole ring and macrocyclization in a one-step process. The two approaches 
proposed to achieve this goal are: 
1) the cyclodehydration-oxidation of the hydroxyamide, and 
2) the use of an oxime resin to facilitate the cyclitive-cleavage strategy. 
The ability of 55 to complex Cu(II) will be tested using the procedure developed by Comba and 
co-workers for the H4pat
1 
macrocycle.
126
 
 
 
 
Figure 23:  Structures of tetraoxazole macrocycle (55) and copper(II)-tetraoxazole 
macrocycle complex (93) 
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2. Results and Discussion 
2.1. Solid Phase Peptide Synthesis 
2.1.1.  Synthesis of Cyclic Octaserine-OtBu (47) 
Our initial efforts focused on the synthesis of 24-membered cyclopeptides via solid phase 
peptide synthesis using microwave energy. Figure 23 shows a retrosynthetic scheme of the desired 
macrocyclic peptide 47, which outlines macrocyclization via the head-to-tail peptide coupling of the 
linear octapeptide precursor 48. This linear octapeptide precursor, 48, was generated via a step-wise 
assembly onto a preloaded Wang resin. Commercially available Wang resin preloaded with Fmoc-
Ser-OtBu (49) (0.8 mmol/g, 0.125 g) was swollen in DMF for 20 min with the aid of a CEM 
Liberty Automated Microwave Peptide Synthesizer (Scheme 11). Next, the resin-bound amino acid 
was deprotected by treating the materials with 20% piperidine in DMF at room temperature for 3 s 
followed by raising the temperature to 75°C and allowing the reaction to proceed for 3 min. The 
liquid was removed and the resin was washed with DMF. The first coupling reaction was performed 
by adding 3 equivalents of HOBT, 3 equivalents of HBTU, and 6 equivalents of DIPEA to 0.5 
mmol of resin-bound Fmoc-Ser-OtBu-OH and agitating the mixture for 5 min at 75°C. These 
reaction cycles were repeated until the desired linear octapeptide, 52,was obtained.  The final 
peptide product was released from the resin by treatment with 25% TFA in DCM for 20 min 
followed by deprotection of the Fmoc protecting group using 20% piperidine in DMF. We 
anticipated that we could obtain the fully protected octapeptide, 53, if the peptidyl resin was treated 
with 25% TFA in DCM. Unfortunately, all our attempts to isolate the linear protected octapeptide 
failed, and only decomposition products were detected. A major drawback to the success of this 
 
 
 
 
 
51 
synthetic route was due to the fact that the orthogonal protecting group, tert-butyl ether, is acid 
labile. To remedy this problem, the synthesis of the macrocyclic peptide was attempted via a 
cyclitive-cleavage approach using oxime resin. 
 
 
 
Figure 24: Retrosynthetic approach for the synthesis of 47, an octaserine macrocycle 
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Scheme 11: Reaction of Wang resin preloaded with Fmoc-Ser-OtBu results in the formation of 51, 
52, and 54. 53 is not formed because the tert-butyl ether groups are cleaved when the resin is treated 
with weak acid. 
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2.1.2.  Synthesis of the Heterocyclic Ring (Oxazole) 
Our next task was to develop a convenient procedure to prepare the 5-membered 
heterocyclic ring (oxazole) directly on a solid support from readily available resin-bound protected 
Fmoc--amino acids. These building blocks would enable the total synthesis of tetraoxazole 
macrocycle 55 (Figure 24). Prior to preparing the macrocycle, our intention was to obtain the 
oxazole-based peptide from a serine residue that could be readily converted into oxazole. 
 
 
Figure 25: Potential retrosynthetic analysis of tetraoxazole macrocycle 55 via a solid phase peptide 
synthesis approach using Wang resin. 
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As shown in Scheme 12, we selected N-Fmoc-Ser-OtBu-Wang resin, 49, as a starting 
material, and the dipeptide was synthesized by using a CEM Liberty Automated Microwave Peptide 
Synthesizer. In order to investigate the efficient preparation of oxazole, we decided to reduce the 
number of amino acids assembled onto the solid support to avoid complication from aggregation or 
steric hindrance due to the peptide sequences. The resin-bound amino acid, 49, was swollen in DMF 
for 20 min, and a 20% piperidine solution in DMF was used to remove the N
 
-Fmoc protecting 
group. The resin was washed several times after being coupled to Fmoc-Phe-OH using 
HOBT/HBTU in the presence of DIPEA. After coupling, we attempted to selectively remove the t-
Bu group using hydrated CeCl3 / NaI in CH3CN at 70°C.
130
 The resin was washed with DCM (2x), 
DMF (3x) and MeOH (1x), and then dried under vacuum. The dried resin, bound to dipeptide 57, 
was subjected to cyclodehydration with TPP, I2 and imidazole
131
 in DCM for 15 min at room 
temperature. The resulting oxazoline was treated with NBS/ K2CO3
132 
in an attempt to prepare the 
oxazole-containing dipeptide 58. Subsequently, adding 25% TFA/DCM gave 59 rather than the 
desired 60.  
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Scheme 12: Failed attempt to remove the tBu-protecting group and to prepare oxazole- containing 
dipeptide using a one-pot synthesis. 
 
In a second attempt, we anticipated that the treatment of 58 with the CeCl3 / NaI system, 
would cleave the OtBu protective group selectively. However, it was difficult to judge whether this 
treatment was efficient or not. In other words, using a solid support makes it difficult to confirm 
that this reaction goes to completion, and it would be challenging to identify the compound before 
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cleaving it from the resin. The difficulty in purifying the dipeptide is likely because treatment with 
TFA/ DCM removes both the resin and the tBu group. Because the amino acid is attached to the 
resin all along the reaction process, it is difficult to determine if the deprotection of the  tBu ether 
occurs upon treatment with CeCl3 / NaI (Scheme 12). 
The failure to remove the t-Bu group needed for oxazole formation led us to shift our effort 
from solid support synthesis to a solution phase synthesis.  
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2.2. Solution Phase Peptide Synthesis (Fmoc-chemistry) 
2.2.1.  Retrosynthetic Approach: Synthetic Studies towards the 
Preparation of a Tetraoxazole Macrocycle 
It was our initial intention to develop a convenient procedure to form an oxazole moiety on a 
solid support, but all attempts met with failure. Furthermore, we were also interested in obtaining a 
strategy for directing macrocyclization from a linear precursor attached to a solid resin bead.  
In this section, we provide the procedure for the cyclization of the -hydroxyamide from a 
serine residue into a substituted oxazole, which is based on work by Wipf and co-workers,
113
 to 
optimize the conditions needed for the cyclization of a linear precursor. For the preparation of 
tetraoxazole macrocycle 55, we envisioned the use of the N-Fmoc- protected amino acids.  
The retrosynthetic analysis for the tetraoxazole macrocycle, 55, is shown in Figure 25. It 
involves cyclizing 61 which consists of alternating oxazoles and amino acid residues. Compound 61 
was prepared via a convergent solution phase synthetic approach, using commercially available 
fluorenylmethyloxycarbonate (Fmoc) and methyl ester (OMe) protected amino acids.  The preferred 
coupling reagents were HBTU and Hünig's base (N, N- diisopropylethylamine, DIPEA). The 
macrocyclization was achieved from the condensation of the free carboxylic acid and the free amine 
of double deprotected linear tetraoxazole amide 61. Compound 61 was obtained by the peptide 
coupling of 64, and, 63 followed by the removal of the Fmoc protecting group and hydrolysis of the 
ester functionality. The dioxazole intermediates were synthesized via condensation of an oxazole-4-
carboxylic acid 66 and a 2-(-amino) oxazole (67) derived from serine and phenylalanine. The 
oxazole moiety was formed via a cyclodehydration/dehydrogenation of the serine residue. The 
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mono-oxazole, 68, was generated by coupling the commercially available Fmoc and methyl ester 
amino acids 71 and 70. 
 
Figure 26:  Retrosynthesis scheme of the tetraoxazole macrocycle,55, in solution-phase, using 
Fmoc-chemistry. 
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2.2.1.1.  Synthesis of N-Fmoc-L-Phe-L-Ser-OMe (69)  
The proposed synthesis of tetraoxazole macrocycle 55 requires that the protected dipeptide, 
69, be prepared by a standard peptide coupling reaction. Addition of Fmoc-protected phenylalanine, 
N-Fmoc-L-Phe-OH (71), to serine methyl ester, HClH-L-Ser-OMe (70), under standard peptide-
coupling conditions gave 69 in 85% yield after recrystallization with hexane (Scheme 13).
30, 133, 134
 
Its purity and structure were confirmed via 
1
H and 
13
C NMR spectroscopy. 
 
 
 
Scheme 13: Chemical reaction for the formation of N-Fmoc-L-Phe-L-Ser-OMe (69). 
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2.2.1.2.   Oxazole Ring Formation  
2.2.1.2.1.  Cyclodehydration Reaction   
Treatment of 69 with Burgess reagent (Scheme 14) promoted cyclization of the -
hydroxyamide of serine to the corresponding oxazoline. First, 69 was dissolved in anhydrous THF. 
Next, Burgess Reagent was added and the reaction mixture was refluxed for 2.5 h.
30, 88, 135
 The 
reaction’s progress was monitored for the disappearance of starting material by TLC. The crude 
reaction mixture was purified by flash column chromatography. Pure N-Fmoc-L-Phe-L-Oxazoline-
OMe (72), eluted with 30:80 ethyl acetate/ hexane, was produced in 45% yield. Its structure and 
purity were verified via 
1
H and
 13
C NMR spectroscopy.  
Yonetaint and co-worker
136
 reported that the pure oxazoline is unstable when exposed to air 
and it decomposed during column chromatography. Apparently, the oxazoline ring re-opens to form 
the corresponding dipeptide.  
The low yield of this reaction was likely due to the decomposition of the oxazoline during 
purification by column chromatography.
137
 Therefore, when ‘Dry Column Vacuum 
Chromatography’ was used to purify our oxazoline the yield increased to 71%. The yield of the 
oxazoline would therefore depend on the amount of the open chain dehydration product formed in 
the competing reaction.
97
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Scheme 14: Synthesis of the oxazoline-containing dipeptide (72).  
 
2.2.1.2.2.   Oxidation of Oxazoline  
The next step was to oxidize the oxazoline to oxazole under basic conditions using 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) and bromotrichloromethane (BrCCl3). DBU and BrCCl3 
were added to N-Fmoc-D-Phe-Oxazoline-OMe (72) dissolved in cold anhydrous DCM. The reaction 
mixture was stirred overnight slowly attaining room temperature. The crude oxazole was subjected 
to base-acid extraction and eluted from a silica gel-containing chromatography column with ethyl 
acetate/ hexane as a gradient system. 
This method was successfully used in oxidizing the oxazoline to the oxazole, 73. 
Disappointingly, the Fmoc-protecting group was lost (Scheme 15). Typically, the DBU/BrCCl3 
oxidation system would be incompatible with the use of Fmoc protecting groups, possibly because 
the Fmoc group is cleaved in the presence of 20% DBU.
138, 139, 140
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Next, attention was directed towards finding a way to oxidize the oxazoline while 
maintaining the Fmoc protecting group. The alternative approach was to attempt to oxidize the 
oxazoline-containing dipeptide, 72, using the Kharasch-Sosnovsky reaction. 
30, 141
 
 
 
 
Scheme 15: Oxidation of the oxazoline-containing dipeptide, 72, using DBU-BrCCl3. 
 
The Kharasch-Sosnovsky reaction involves a cocktail of CuBr, Cu(OAc)2, and t-
butylperbenzoate. The oxazoline was oxidized by refluxing 72, CuBr, Cu(OAc)2, and t-
butylperbenzoate in benzene (Scheme 16). After 8 h, the reaction mixture was cooled to room 
temperature and washed with base to remove the excess copper. The crude product was purified 
using flash column chromatography yielding pure N-Fmoc-L-Phe-L-Oxazole-OMe (68) in 68% 
yield. The structure and purity of 68 were confirmed via 
1
H, and 
13
C NMR spectroscopy. 
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Scheme 16: Synthesis of oxazole-containing dipeptide, 68, using Kharasch-Sosnovsky reaction 
conditions. 
 
2.2.1.3.  Acid Deprotection 
Both the Fmoc and methylester protecting groups are base labile. The selective cleavage of 
the methyl ester using an aluminium chloride (AlCl3) and N,N-dimethylaniline (DMA) reagent 
system is dependent on the molar ratio of AlCl3 to DMA.
142, 143
 Thus, the chemoselective removal of 
the methyl ester protecting group was obtained with a 9:14 molar ratio of AlCl3/DMA.  
 
The reaction mixture containing 68 and AlCl3/DMA (9:14) dissolved in anhydrous DCM 
was refluxed for 8 h (Scheme 17).  The reaction was monitored via TLC for the disappearance of 
starting material. We found this reaction produced a mixture of products (many spots on the TLC 
plate). The reaction mixture was first treated with acid and the crude product was purified by flash 
column chromatography. Despite the longer reaction time only 10% of pure N-Fmoc-D-Phe-
Oxazole-OH (66) was obtained. 
1
H NMR spectra indicated that a trace of DMA remained trapped 
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with 66. The disappearance of the proton signal at δ = 3.94 ppm due to the loss of OCH3 confirmed 
that the methyl ester was cleaved. 
It was thought that the reaction would lead to selective cleavage of the OMe group. 
However, analysis of the by-products showed that some of the Fmoc protecting group was lost 
during purification of the dipeptide via flash column chromatography. 
In order to increase the yield of this reaction, selective cleavage of the OMe group in 68 was 
attempted by using CaCl2, iPrOH/ H2O and NaOH.
144
 This procedure also afforded a disappointing 
yield of 66 in that no improvement in yield was obtained by carrying out the reaction with CaCl2, 
iPrOH/ H2O and NaOH. Our failure to deprotect OMe selectively led us to use another N-terminal 
protecting group that is cleaved by acid, i.e., t-butyloxycarbonyl, (Boc). 
 
 
 
Scheme 17: Selective deprotection of the methyl ester protecting group in 68. 
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2.2.2.  Retrosynthetic Approach: Solution Phase Peptide Synthesis 
of the Tetraoxazole Macrocycle (Boc-chemistry) 
This section describes the results obtained when t-butyloxycarbonyl (Boc) was used as a 
protecting group for N-terminal amino acids. By using Boc instead of Fmoc it was anticipated that 
the methyl ester functionality could be selectively hydrolyzed under basic condition. 
The retrosynthesis analysis for tetraoxazole macrocycle 55, shown in Figure 26, involves 
preparing peptides with alternating oxazoles and amino acid residues prior to macrocyclization. The 
synthesis of macrocyclic tetraoxazole precursors were carried out via a convergent solution phase 
synthesis approach using commercially available Boc- and methyl ester (OMe)- protected amino 
acids, coupling reagents (HBTU) and Hünig's base (N, N- diisopropylethylamine, DIPEA). The 
desired macrocycle, 55, results upon the condensation of the free acid and free amine of linear 
tetraoxazole amide, 74. The double deprotection of 75 yields 74. The coupling of the Boc- protected 
dioxazole precursor, 76, with the carboxy-protected dioxazole precursor, 77, gives 75. The 
dioxazole precursors, 76 and 77, are obtained by the selective deprotection of N-Boc, CO2-Me 
protected dioxazole, 78. Condensation of the oxazole-4-carboxylic acid, 79, and a 2-(-amino) 
oxazole, 80, derived from serine and phenylalanine gives 78. The oxazole moiety was formed via 
the cyclodehydration/dehydrogenation of the serine residue. The mono-oxazole, 81, was generated 
by coupling the commercially available amino acid building blocks, (83 and 84) followed by 
cyclodehydration oxidation. 
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Figure 27: Retrosynthetic approach towards the tetraoxazole macrocycle using solution-phase 
peptide synthesis and Boc-chemistry. 
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2.2.2.1.  Synthesis of Protected Dipeptide N-Boc-L-Phe-L-Ser-OMe 
(82) 
The protected dipeptide, N-Boc-L-Phe-L-Ser-OMe (82), was prepared using N-Boc-L-Phe-
OH (84) and HClH-Ser-OMe (83) as both were commercially available, Scheme 18. Condensation 
of 84 and 83 was carried out using the coupling reagent O-(benzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate (HBTU) and Hünig's base (DIPEA) in dry DCM. The reaction 
mixture was subjected to an acid-base extraction to remove the excess coupling agent (HBTU) as 
well as any by-products. Purification of the crude mixture by flash column chromatography 
afforded the protected dipeptide, N-Boc-L-Phe-L-Ser-OMe (82), in 67% yield. Analysis of 
1
H NMR 
and 
13
C NMR spectra of the pure compound was consistent with that expected for 82. It should 
however be noted that the 
1
H NMR and 
13
C NMR chemical shifts of a mixture of 84 and 83 are 
almost identical to those of 82. The identity and purity of 82 were therefore confirmed by melting 
point analysis. 
 
Scheme 18: Synthesis of the N-Boc protected dipeptide, 82. 
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2.2.2.2.   Oxazole Ring Formation 
2.2.2.2.1.   Cyclodehydration Reaction 
 
The oxazoline ring was prepared in two different ways. The first method involved the 
treatment of N-Boc-L-Phe-L-Ser-OMe (82), dissolved in THF, with Burgess reagent (Scheme 19) 
yielding 85. The intramolecular cyclization was achieved with inversion of configuration at the 
serine -carbon.145, 146 The reaction was monitored, via TLC, for the disappearance of starting 
material. The crude product was purified via “Dry Column Vacuum Chromatography” with natural 
silica gel and ethyl acetate- hexane as a gradient system giving N-Boc-L-Phe-Oxazoline-OMe (85) 
in 84% yield.  
The two spots visible on the TLC plate were thought to arise because of the formation of 
diastereoisomers of the oxazoline. 
1
H NMR confirmed the oxazoline structure by the absence of the 
resonances of the serine hydroxyl group and adjacent amide protons. The multiplet signals at 4.73 
ppm (2H) and 4.60 ppm (1H) were assigned to the protons attached to the oxazoline ring.  
Alternatively, the cyclodehydration of the protected dipeptide, N-Boc-L-Phe-L-Ser-OMe 
(82), was carried out using diethylaminosulfur trifluoride (DAST) (Scheme 19).
87, 147, 148 
N-Boc-L-
Phe-L-Ser-OMe (82) was dissolved in anhydrous DCM and cooled to -78°C. DAST was then added 
to the solution and stirred at the same temperature for 1 h. Addition of K2CO3 to the reaction 
mixture with stirring for 1 h resulted in the intramolecular cyclization of 82 yielding the oxazoline 
intermediate. The reaction was monitored by TLC until the starting material could no longer be 
detected. The crude reaction mixture was subjected to an acidic workup. The product was purified 
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by flash column chromatography yielding pure N-Boc-L-Phe-Oxazoline-OMe (85) (88% yield). 
The structure and purity were verified using 
1
H NMR and 
13
C NMR spectroscopy. 
 
 
 
Scheme 19: Cyclization of the N-Boc protected dipeptide (82) yielding the oxazoline (85). 
Cyclization was accomplished using either the Burgess reagent or with DAST/K2CO3. 
 
2.2.2.2.2.   Oxidation of Oxazoline 
 
The resulting oxazoline intermediate was subjected to oxidation using a 1,8-
diazabicycloundec-7-ene (DBU) - bromotrichloromethane system (Scheme 20).
133, 149, 98
 N-Boc-L-
Phe-Oxazoline-OMe (85) was dissolved in anhydrous DCM and cooled to 0°C. The base, DBU, 
was then added to the reaction mixture followed by the addition of BrCCl3. The reaction was 
allowed to stir overnight while warming up to room temperature. TLC analysis revealed the absence 
of oxazoline and the presence of the product along with some impurities. Upon completion, the 
reaction mixture was neutralized and the product purified by flash column chromatography. The 
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mono-oxazole dipeptide amide, N-Boc-L-Phe-Oxazole-OMe (81), was produced in 91% yield. Its 
structure and purity were confirmed by 
1
H NMR and
13
C NMR spectroscopy. In particular, the 
distinctive singlet appearing at δ= 8.23 ppm (s, 1H; OCH=C(oxaz)) in the 1H NMR spectrum is 
characteristic of the presence of the oxazole ring. 
 
 
Scheme 20: Synthesis of N-Boc-Phe-Oxa-OMe (81) by oxazoline oxidation. 
 
2.2.2.3.  Amine Deprotection: Synthesis of Dipeptide HClH2N-L-
Phe-Oxazole-OMe (80)  
In order to generate the linear precursor, the pure mono-oxazole dipeptide amide, 81, was 
divided into two portions. The amine functionality of one portion of 81 was deprotected to yield 80 
(Scheme 21).
54, 71, 150
 while the ester functionality of the remaining portion was hydrolyzed to give 
79 (Scheme 22). More specifically, 80 was formed when the dipeptide, 81, dissolved in THF, was 
treated with a 4 M HCl-dioxane solution cooled to 0°C. After 4 h, the starting material could no 
longer be detected by TLC, indicating that the reaction went to completion. The solution was 
washed with dry diethyl ether. Concentration of the diethyl ether phase in vacuo gave HClH2N-L-
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Phe-Oxazole-OMe (80). The disappearance of the N-Boc protecting group was confirmed by NMR 
spectroscopy. The NMR data of 80 were similar to that of 81 with the exception of the 
disappearance of the proton signal at δ = 1.43 ppm (s, J = 7.8 Hz, 9H) and the 13C signal at 28.24 
ppm due to the N-Boc group. The product was used without further purification. 
 
 
 
Scheme 21: Synthesis of the hydrochloride salt of H2N-L-Phe-Oxazole-OMe (80). 
 
2.2.2.4.  Acid Deprotection: Synthesis of N-Boc-Phe-Oxazole-OH 
(79) 
The remaining mono-oxazole dipeptide amide, 81, was treated with LiOH in THF/H2O (1:1) 
to hydrolyze the methyl ester group (Scheme 22).
151, 152, 153
 After the reaction had gone to 
completion (3 h), the reaction mixture was concentrated to half of the original volume. The 
resulting aqueous mixture was neutralized and concentrated in vacuo to afford N-Boc-L-Phe-Oxa-
OH (79). 
1
H and 
13
C NMR spectroscopy were used to confirm the identity and the purity of the 
product. 
1
H and 
13
C NMR analysis confirmed the absence of methyl ester signals at 3.82 ppm (s, 
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3H) and 52.46 ppm, respectively. The product was used in coupling reaction described below 
without further purification.  
 
 
 
Scheme 22: Synthesis of N-Boc-L-Phe-Oxazole-OH (79). 
 
2.2.2.5.  Synthesis of N-Boc-L-Phe-L-Oxazole-L-Phe-Oxazole-OMe 
(78) 
The protected linear dioxazole amide, 78, was assembled by coupling the free acid, N-Boc-
L-Phe-Oxa-OH (79), with the free amine, HClNH2-L-Phe-OMe (80), using HBTU and Hünig’s 
base (DIPEA) in anhydrous DCM (Scheme 23). The reaction was allowed to proceed under 
nitrogen atmosphere at room temperature and its progress was monitored via TLC. After washing 
the reaction mixture with acid followed by base, the crude product was purified using flash column 
chromatography. Pure 78 (73% yield) was eluted with 30:80 ethyl acetate/ hexane. 
1
H and 
13
C 
NMR spectroscopy were used to confirm its structure and purity. Characteristic peptide resonances 
in the 
1
H NMR spectrum of 78 included broad singlets at δ = 8.13 and 8.08 ppm attributable to the 
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oxazole protons, and doublets of doublets between 7.49 and 5.16 ppm corresponding to amide NH 
protons. 
 
 
 
Scheme 23: Synthesis of N-Boc-L-Phe-L-Oxazole-L-Phe-Oxazole-OMe (78). 
 
2.2.2.6.   Synthesis of Protected Linear Tetraoxazole Amide (75) 
Prior to synthesizing the protected linear tetraoxazole amide, 75, the protected linear 
dioxazole amide, 78, was divided into two portions. The Boc group in one portion of 78 was 
removed (Scheme 24) using an HCl/dioxane mixture in THF. The amine deprotection was 
monitored via TLC and was complete in 4 h. The residue was washed with dry diethyl ether which 
was subsequently concentrated in vacuo to furnish HClNH2-L-Phe-Oxazole-L-Phe-Oxazole-OMe 
(77). Its structure and purity were confirmed via 
1
H NMR and 
13
C NMR spectroscopy. The NMR 
data of the deprotected product, 77, was almost identical to that of protected 78 except for the 
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absence of the signals for the Boc group at δ = 1.45 ppm (s, 9H) in the 1H NMR spectrum and 28.29 
ppm in the 
13
C NMR spectrum. 
The remaining portion of 78 was treated with LiOH in THF/H2O (1:1) to hydrolyze the 
methyl ester-protecting group. The reaction was completed in 4 h as confirmed by TLC. When 
complete, the crude was concentrated to one-half volume. The resulting aqueous mixture was 
purified via an acidic wash and concentrated in vacuo. This provided the required acid N-Boc-L-
Phe-Oxa-Phe-Oxa-Phe-OH (76). The
 1
H and 
13
C NMR spectroscopy were used to verify the product 
and its purity. The methyl ester signals at 3.93 ppm (s, 3H) and 48.32 ppm were no longer visible in 
1
H and 
13
C NMR spectra, respectively. Compound 76 was used in the subsequent coupling reaction 
without any further purification.  
 
 
Scheme 24: Removal of the methyl ester and t-butyloxycarbonyl protecting groups from protected 
linear dioxazole amide 
 
The next phase of the synthesis required coupling compounds 76 and 77 with the aid of 
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HBTU and DIPEA in anhydrous DCM. The reaction mixture was stirred at room temperature under 
a nitrogen atmosphere for 24 h. The yield of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe-
Oxazole-L-Phe-Oxazole-OMe (75) was 57%. Trace amounts of N, N’-diisopropylurea were 
detected in the 
1
H and
 13
C NMR spectra of 75. We believe that the solvent system used for the flash 
column chromatography allowed the elution of both 75 and N, N’-diisopropylurea. Therefore, an 
alternative coupling procedure that involved the water-soluble coupling agent 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) was used since the urea by-product could be readily 
removed by aqueous extraction.
154, 155
 Using this coupling system proved to be more successful and 
the overall yield was 10% better than that obtained using HBTU (Scheme 25). The 
1
H and
 13
C NMR 
spectra were consistent with what one would expect for 75. Characteristic peptide resonances in the 
1
H NMR spectrum of 75 included doublets of doublets at 7.52 ppm (1H), 7.28 ppm (1H), and 7.02 
ppm (2H), corresponding to four amide protons. In addition, broad singlets at 8.12 ppm (3H) and 
8.08 ppm (1H), attributable to four oxazole protons were observed. The 
1
H and 
13
C NMR data 
obtained for 75 were identical to those reported in the literature.
153b 
 
Scheme 25: Synthesis of the protected linear tetraoxazole amide, 75.  
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2.2.2.7.   Double Deprotection of the Linear Precursor to Form 74 
A stepwise approach was employed to generate the double deprotected linear tetraoxazole 
amide, 74 (Scheme 26). By adding 2N LiOH in THF/H2O the methyl ester was converted to the 
carboxylic acid functionality after 4 h. The reaction progress was monitored by observing the 
appearance of the free acid and the disappearance of starting material via TLC. After standard work 
up, the Boc protecting group was removed from the crude product using an HCl/dioxane mixture 
(4M) in anhydrous THF. The reaction was allowed to proceed to completion at room temperature, 
and verified via TLC by observing for the presence of the free amine and the disappearance of 
starting material. The resulting amine was washed with dry diethyl ether and collected by filtration 
to furnish the double deprotected linear precursor, 74. This product was used in the 
macrocyclization step without any further purification. 
The NMR data of the deprotected product 74 were almost identical to that of the starting 
material with the exception of the disappearance of the signals for the tertiary butyl group at δ = 
1.42 ppm (s, 3H) and the methylester group at δ = 3.90 ppm (s, 9H) in the 1H NMR spectrum and at 
δ = 28.26 and 39.97 ppm in the 13C NMR spectrum.  
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Scheme 26: Stepwise double deprotection strategy for the formation of the linear tetraoxazole 
amide, 74. 
 
2.2.2.8.   Macrocyclization of the Linear Tetraoxazole-Containing 
Peptide to Form Tetraoxazole Macrocycle 
Typically, the macrocyclization reaction was carried out under highly diluted conditions 
(<0.001M) to disfavor the unwanted intermolecular reaction of the peptide
156, 102, 157
. In order to 
achieve the cyclization of linear deprotected peptide 74 and maximize the yield of cyclization, the 
coupling reagent O-[(1-cyano-2-ethoxy-2-oxoethylidene)amino]-oxytri(pyrrolidin-1-yl) 
phosphonium hexafluorophosphate (PyOxP) and DIPEA were used to push the reaction to 
completion. PyOxP is a novel coupling reagent of the oxyma-based family of phosphonium salts. 
This phosphonium salt gives high coupling efficiency not only in peptide coupling but also in cyclic 
peptide synthesis because of its higher propensity to reduce racemization. In contrast to HBTU, 
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PyOxP gives an active ester that is extremely reactive due to the low hindrance and acidity, which 
results in an excellent leaving group.
158a 
To generate the tetraoxazole macrocycle, 55, PyOxP and 
DIPEA (Scheme 27) were added to a solution of 74 in DMF (0.001M). The reaction mixture was 
stirred at room temperature under a nitrogen atmosphere and the progression of the reaction was 
monitored by TLC. After 3 days there was no evidence of the presence of the starting material. The 
crude product was concentrated in vacuo to a quarter of its volume. The crude product was washed 
with dilute acid followed by dilute base. Then, DCM was used to extract the product from the 
aqueous phase. After the removal of DCM in vacuo, the by-product was removed by trituration with 
hot hexane twice to afford 55 in 45% yield. This was confirmed by 
1
H NMR spectroscopy. 
 
The 
four amide protons resonate between 7.16 – 7.11 ppm while the protons of the oxazole rings are 
found at 8.13 ppm. This is consistent with the spectroscopic data of 55 reported in a patent.
158b
 
 The success of using the orthogonal protecting group (Boc) to synthesize the tetraoxazole 
macrocycle led us to investigate the compatibility of Boc with an oxime resin so that the 
macrocycle could be produced in higher yield by a cyclitive-cleavage strategy. 
 ‘  
Scheme 27: Macrocyclization of 74. 
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2.2.3.  Retrosynthetic Approach: Solid Phase Peptide Synthesis 
The tetraoxazole macrocycle, 55, can be efficiently synthesized by exploiting elongation-
cyclization-cleavage sequential reactions on a Kaiser-oxime resin,
159, 160
 which incorporates a 
combination of solution and solid phase synthesis (Figure 27). The tetraoxazole-containing 
precursor (86) was assembled by solid phase synthesis. This involved the coupling of 79 to an 
oxime resin by a standard method followed by the stepwise addition of three more molecules of 79. 
The fragment 79 was afforded by coupling the commercially available t-butyloxycarbonyl (Boc) 
and methyl ester protected amino acids 84 and 83 and subjecting the product to cyclodehydration 
followed by oxidation. 
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Figure 28: Retrosynthetic strategy for the formation of the tetraoxazole macrocycle, 55, via solid 
phase peptide synthesis and cyclization cleavage (SPPS-CC) from an oxime resin. 
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2.2.3.1.   Solution Phase Synthesis of N-Boc-L-Phe-L-Oxazole-OH 
(79) 
The synthesis of 79 was carried out by first coupling the free acid 84 and free amine 83 to 
give the corresponding dipeptide, N-Boc-L-Phe-L-Ser-OMe (82) (Scheme 28). Subsequently, 
subjecting 82 to cyclodehydration-oxidation followed by acid conversion resulted in the formation 
of 79. Firstly, the free acid, 84, and the free amine, 83, were coupled using HBTU and DIPEA in 
anhydrous DCM to give N-Boc-L-Phe-L-Ser-OMe (82) in 85% yield. The structure and purity of 
the compound were verified by 
1
H and 
13
C NMR spectroscopy. Next, heating 82 to reflux with 
Burgess reagent in anhydrous THF for 2 h gave N-Boc-L-Phe-L-Oxazoline-OMe (85) in 84% yield 
after purification of the crude product using dry column chromatography. The 
1
H and 
13
C NMR 
spectral data obtained were consistent with that expected for 85. Oxidation of oxazoline 85 with 
DBU-BrCCl3 in DCM gave N-Boc-L-Phe-L-Oxa-OMe (81) in 91% yield after purification. The 
1
H 
and 
13
C NMR spectra of 81 were recorded and are what is expected based on the structure of 81. 
Finally, the carboxylic acid moiety of 81 was deprotected using LiOH in THF/H2O (1:1). The 
reaction went to completion, and resulted in the formation of N-Boc-L-Phe-L-Oxa-OH (79). 
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Scheme 28: Synthesis of N-Boc-L-Phe-L-Oxa-OH (79). 
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2.2.3.2.   Synthesis of Tetraoxazole-containing Macrocycle 55 Using 
Solid Phase Peptide Synthesis 
A stepwise strategy was used to generate the linear heterocycle-containing peptide bound to 
resin (Scheme 29) needed for the solid phase synthesis of 55. The intermediates on the resin were 
not structurally characterized. However, since the final compound 55 was isolated and characterized 
by NMR, it is assumed that the intermediates on the resin (87, 90, 91, 92, 86) were successfully 
prepared. First, 79 was loaded onto the commercially available p-nitrobenzophenone oxime resin 
(88). This involved adding a solution containing 79 in DMF and HBTU to 88 followed by the 
addition of DIEPA. A Kaiser test was conducted to monitor the progress of the reaction. The Kaiser 
test is a quantitative ninhydrin test used in the detection of primary and secondary amines. The 
solution turns from blue to yellow when the coupling reaction is complete. This occurred after the 
solution had been agitated for 12 h. The resin was collected by filtration and washed with DMF 
(5x), DCM (5x), and DMF (1x). Next, acetylation of the oxime functionality on the resin using 
50/50 (v/v) acetic anhydride/DMF with DIPEA
161 
gave N-Boc-L-Phe-Oxa-resin (87). The t-Boc 
group in 87 was removed using 25% TFA/DCM followed by DIPEA treatment to generate the free 
amino group.
162
 A solution containing 79, HBTU, and HOBt in DMF resulted in formation of the 
activated ester 89. Adding 89 to the preloaded resin, 90, in the presence of DIPEA in DMF yielded 
N-Boc-L-Phe-Oxa-L-Phe-Oxa-resin (91) after 3 h of stirring. Then, 91 was subjected to a 
subsequent amine deprotection step using 25% TFA/DCM. Two more molecules of 79 were 
coupled to the resin, using the procedure described above, giving N-Boc-L-Phe-Oxa-L-Phe-Oxa-L-
Phe-Oxa-L-Phe-Oxa-resin (92). Each coupling was monitored by the Kaiser test to confirm 
completion of the reaction. Once the peptide sequences were completed, 92 was treated with 25% 
 
 
 
 
 
84 
TFA/DCM followed by DIPEA to give 86. Compound 86 was treated with 6% acetic acid and 
agitated for 3 days to complete the cyclization-cleavage reaction. Acetic acid is used as a catalyst 
for the cyclization cleavage reaction being able to activate the oxime ester linkage bond for 
nucleophilic attack by free amine.
160, 163
 Finally, the resin was washed with DCM and the filtered 
solution was concentrated in vacuo to give 55 in 20% yield.  
The tetraoxazole macrocycle, 55, was successfully prepared in both of the 
macrocyclization protocols. However, the yield of 55 obtained by convergent solution phase 
peptide synthesis is much higher than that obtained by the cyclitive cleavage strategy (SPS-CC). 
The low yield of 55 using SPS-CC was not expected because simultaneous cyclization and 
cleavage is allowing the cyclic product to be isolated in high yield and purity. Although, the 
reason for low yield of 55 using the SPS-CC strategy is not known, it is possible that the oxime 
resin is labile to nucleophiles thus leading to the loss of some peptide from the resin upon 
neutralization with base after the removal of t-Boc under acidic condition.
164 
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Scheme 29: Synthesis of N-Boc Protected Peptidyl-bond oxime resin and the head to tail 
cyclization with concomitant cleavage from resin. 
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2.3. UV-Vis Spectrophotometric Titration of Tetraoxazole 
Macrocycle with Cu(II) 
Having prepared 55, the next objective was to test its ability to complex metal ions. 
Comba and co-workers
127
 studied the Cu(II) coordination chemistry of the cyclic pseudo peptide 
H4pat
1
, a dimethylimidazole analogue of the naturally occurring cyclic peptides, patellamide A-F 
and ascidiacyclamide. Because of the similarities between H4pat
1 
and 55, it was decided to use 
the protocol developed by Comba and co-workers
127
 to study the interaction of Cu(II) with 55.  
The first part of the experiment involved recording the UV spectra of a solution of the 
tetraoxazole after the stepwise addition of 0.25 equivalents of Cu(II) until a tetraoxazole to 
Cu(II)  ratio of 1:4 was attained (Figure 29). The absorption band at 840 nm ( = 28 M-1 cm-1) is 
presumably due to the d-d transition of Cu(II). Interestingly, the relationship between the 
absorbance at 840 nm and the amount of Cu(II) added to the macrocycle was linear beyond the 
addition of 2 equivalents of the metal ion (see inset of Figure 29). 
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Figure 29: UV-Vis spectra of the titration of the tetraoxazole macrocycle (1.5 mM) with Cu(II) 
in methanol. The titration was performed with 0-4 equivalents of Cu(II), in 0.25 eq steps. 
 
 In another set of experiments, an incremental amount of base (tetrabutylammonium 
ethoxide) was added to a solution of the tetraoxazole macrocycle supplemented with 2 
equivalents of Cu(II). The addition of base resulted in a shift of the d-d transition from 840 nm to 
634 nm ( = 174 M-1cm-1), Figure 30 a. Upon the addition of > 2 equivalents of base, a shoulder 
at 537 nm emerged (Figure 30 b). The intensity of the absorption bands at 634 nm and 537 nm 
increased dramatically following an increase in the amount of base from 2.0 to 2.25 equivalents. 
The intensity remained constant when more than 2.25 equivalents of base were added. 
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Figure 30: UV-Vis spectra of macrocycle-copper complex (1:2) titrated with 
tetrabutylammonium ethoxide. (a) 0-2 equivalents of base. (b) 2-5 equivalents of base. 
The inset shows a plot of the absorbance at max= 634 nm (squares) and max= 537 nm 
(diamonds) as a function of base concentration. 
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Similarly, Comba and co-workers, found that the addition of copper (II) to a H4pat
1
 
caused the emergence of a d-d band at max = 714 nm (see Figure 31 a).
127
 Addition of the base, 
(n-Bu4N)(OMe), to the H4pat
1
-Cu(II) solution resulted in an increase in the absorbance and the 
formation of a new band at 685 nm (Figure 31 b). Upon addition of up to 2-3 equivalents of base 
a shoulder at 550 nm emerged (Figure 31 c). The authors observed that the intensities of the 
absorption bands at 685 and 550 nm have an inflection point after the addition of two equivalents 
of base (Figure 31 c).
127
 The intensity of the absorption band at 685 nm increased upon addition 
of up to three equivalents of base, a result similar to that recorded for the absorption band at 550 
nm (Figure 31 d). Comba and co-workers suggested that the absorption maximum at 685 nm 
correlates with the dinuclear copper(II) complex [Cu2
II
 H2pat
1
 (OH2)]
2+
, which is converted into 
the hydroxo species upon deprotonation [Cu2
II
H2pat
1
(OH)]
+ 
(Figure 32). The intensity of the 
spectra marginally decreased during the addition of 4-5 equivalents of base. This decrease was 
thought to be caused by the formation of a bluish precipitate (most likely Cu(II) methoxide or 
hydroxide formed under highly basic conditions), resulting in the removal of copper(II) from the 
solution.  
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Figure 31: UV-Vis spectra of the titration of H4pat
1 
(1.25 mM) with Cu(II) in methanol. (a) 
titration of H4pat
1 
with
 
0-2 equivalents of Cu(II) in 0.2 eq steps, (b) titration of H4pat
1
/copper (II) 
(1:2) with 0–2 equivalents of (n-Bu4N)(OMe) in 0.2 eq steps, (c) titration of H4pat
1
/copper (II) 
(1:2) with 2-5 equivalents of base in 0.2 eq steps, (d) absorbance of the bands at  = 685 and 550 
nm as a function of equivalents of base.
127
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Figure 32: Proposed copper(II) complexation equilibria of H4pat
1
 (S = methanol).
127 
 
 
It is therefore tempting to assign the species responsible for the absorption at 634 nm in 
the Cu(II)- 55 system to the dinuclear Cu(II) compound, 93, as it behaved in a similar manner to 
that reported for [Cu2
II 
H2pat
1
(OH)]
+
. 
127 
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Figure 33: Structure of copper(II)- tetraoxazole macrocycle (55) complex 
 
However, a solution containing only copper(II) and tetrabutylammonium ethoxide gave a 
UV-Vis spectrum identical to that found for the solution of the tetraoxazole macrocycle 
supplemented with 2 equivalents Cu (II) at high base concentration (compare Figures 34 and 30 
b). Based on this observation we are unable to conclude that the dinuclear Cu(II)-tetraoxazole 
macrocycle was formed. This also brings into question the interpretation of the results reported 
by Comba and co-workers.
127 
In order to confirm the species formed in the Cu(II)-tetraoxazole 
macrocycle system over a range of base concentrations another technique such as ESI-MS would 
have to be utilized. 
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Figure 34: UV-Vis spectra of the titration of copper(II) (6 mM) in methanol with 
(tetrabutylammonium ethoxide). The titration of (0-5 equivalents) of base was performed in 0.5 
eq steps. 
 
2.4. Conclusion and Future Direction 
We have shown how the tetraoxazole macrocycle, 55, can be synthesized using a convergent 
solution phase peptide synthetic strategy from the readily available starting materials, namely, N-
Boc-L-Phe-OH and HClNH2-L-Ser-OMe. The key to this synthetic strategy was the stepwise 
coupling of peptides to produce di-, tetra- and octa- peptides. The treatment of the -hydroxyamide 
functionalities with the Burgess reagent or DAST followed by DBU/BrCCl3 resulted in 
cyclodehydration-dehydrogenation giving the desired oxazole moiety. The convergent synthesis 
generated the precursor 75. Cyclization of 74 to form 55 proved to be challenging but with PyOxP 
as the coupling agent, 55 was formed in 45% yield. 
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The solid phase peptide synthesis (SPS-CC) method with oxime resin also provided a 
highly efficient strategy to synthesize the desired macrocycle 55 in 20% yield. It was concluded 
that the treatment of the peptidyl resin with acetic acid led to the concomitant cleavage of oxime 
resin to obtain the macrocycle. 
We attempted to investigate the ability of 55 to complex copper(II) ions using UV-Vis 
spectroscopy. Although the UV-Vis spectrum of a Cu(II)-55 solution changed as a function of a 
hydroxide concentration, the change was identical to that observed for a solution not containing 
55. Unfortunately, the results were not conclusive. 
Future work will be focused on crystallizing the macrocycle to obtain its X-ray structure. 
EPR and NMR spectroscopies as well as electrospray ionization mass spectrometry (ESI-MS) could 
be used to characterize the copper(II) complexes formed in solution. In addition, a better 
understanding of the coordination chemistry could be gained by determining the X-ray structures of 
the metal-free macrocycle and the dinuclear copper(II) complex of tetraoxazole macrocycle. 
Molecular modeling could be performed to gain better insight into the molecular structure of the 
tetraoxazole macrocycle and its complex, and to understand and predict the behaviour of molecular 
systems. 
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3. Experimental Section   
3.1. Experimental Methods  
3.1.1.  General Remarks  
Solvents were purchased from Sigma-Aldrich or Fisher Scientific and used without 
further purification. They include hexane, tetrahydrofuran (THF), benzene, ethyl acetate 
(EtOAc), methanol (MeOH) and dichloromethane (DCM). Diethyl ether was dried over metallic 
sodium and freshly distilled prior to use. All protected D-amino acids, purchased from Chem-
Impex, were of the highest purity available. O-benzotriazole-N,N,N’,N’-
tetramethyluroniumhexafluorophosphate (HBTU), hydroxybenzotriazole (HOBt), N,N-
diisopropylethylamine (DIPEA), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and 
trifluoroacetic acid (TFA), were purchased from Chem-Impex. Oxime resin with a substitution 
level around 0.61 mmol/g was purchased from Chem-Impex. Aluminum-backed thin layer 
chromatography (TLC) plates, with a 254 nm fluorescence indicator, were purchased from 
Silicycle and used to monitor all the reactions. Silica gel (Silicaflash P60, 230-400, 40-63 μm 
particle size) was obtained from Silicycle.  Nuclear magnetic resonance spectra (
1
H NMR and 
13
C NMR) were recorded at room temperature on a Bruker Avance 500 MHz NMR 
spectrometer. Chemical shifts were relative to TMS or the deuterated solvents CDCl3 (δH = 7.26 
ppm and δC = 77.2 ppm), DMSO (δH= 2.50 ppm and δC= 93.5 ppm), or CD3OD (δH = 3.31 ppm, 
δH = 7.74 ppm, and δC = 49.2 ppm). 
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3.2.   General Experimental Procedures 
3.2.1.  Solution Phase Peptide Coupling Procedures 
The di-, tetra-, and octa- peptide-coupling reactions were carried out under nitrogen in 
dichloromethane (DCM) or tetrahydrofuran (THF). The free carboxylic acid (1equiv.), HBTU (1.3 
equiv.), DIEPA (3.5 equiv.), and the free amine (1 equiv.) were added to anhydrous DCM or THF 
at 0°C to generate a 0.1 M solution.  The mixture was stirred at room temperature for 24 h and the 
reaction progress was monitored by TLC. The organic solution was washed with 0.5 N NaHSO4, 
H2O, saturated (aqueous) NaHCO3 and brine, dried over MgSO4 and filtered. The filtrate was 
concentrated in vacuo. The residue was purified by column chromatography on silica gel. 
 
3.2.2.  Boc-Removal Reaction (Amine Deprotection) 
The Boc-protected compound (0.2 mmol) was dissolved in THF (0.1 M) and the solution 
was cooled to 0°C under N2 gas. A solution of HCl/ dioxane (4 M, 4 mL) was added in one portion. 
The ice bath was removed after 30 min, and stirring continued at room temperature for 4 h. The 
mixture was concentrated in vacuo. The residue was then washed with dry diethyl ether and 
collected by filtration to provide the hydrochloride, which was used in the next step without further 
purification. 
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3.2.3.  Methyl Ester Hydrolysis (Acid Deprotection) 
Acids were deprotected by slowly adding LiOH (2 M, 2.3 mmol) to a stirred solution of 
oxazole ester in THF/H2O (1:1) at 0°C. The reaction mixture was stirred at 0°C for 1.5 h. The 
mixture was allowed to warm to room temperature over a period of 2 h. Stirring continued until 
TLC analysis showed the consumption of starting material. The solution was concentrated to one-
half the volume. The resulting aqueous mixture was acidified with 1 M HCl to a pH2 at 0°C. The 
product was extracted from the aqueous phase using 2 x 10 mL portions of EtOAc; the organic 
layers were combined, washed with brine, dried over MgSO4, and filtered. The filtrate was 
concentrated in vacuo. The crude product was used in the next step without further purification. 
 
3.2.4.  Oxazole Formation 
3.2.4.1.   Oxazoline Generation with Burgess Reagent 
Burgess reagent (2.6 g, 11 mmol) was added to 3.7 g of peptidyl-phenylserine (1 mmol) in about 
100 mL of THF and the mixture was refluxed for 2 h.  The solvent was removed in vacuo to give 
the crude product which was subsequently purified by flash chromatography. 
3.2.4.2.   Oxazoline Oxidation with DBU 
Oxazoline (2.27 g, 6.5 mmol) was dissolved in 65 mL of anhydrous DCM and the solution 
cooled to 0 °C in an ice bath.  DBU (1.95 mL, 13 mmol) was added dropwise followed by BrCCl3 
(1.28 mL, 13 mmol). The mixture gradually attained room temperature as it was left to stir 
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overnight. The mixture was washed with saturated aqueous NH4Cl, and the product was extracted 
from the aqueous phase with 30 mL portions of EtOAc. The combined organic phases were washed 
with brine, dried with MgSO4, and concentrated in vacuo. The residue was purified by flash 
chromatography. 
 
3.2.5.  Macrocyclization 
The linear octa-peptide (0.1 mmol) was cyclized by treatment with 0.11 mmol of PyOxP and 
0.44 mmol of DIPEA in DMF. After being stirred for 3 days, the mixture was washed with 
saturated aqueous NaHSO4, H2O and brine, dried over (MgSO4) and concentrated in vacuo. 
 
3.3. Preparation of Tetraoxazole Macrocycle (55) 
3.3.1.  Synthesis N-Fmoc-L-Phe-L-Ser-OMe (69) 
The dipeptide, 69, was synthesized using the following solution phase peptide coupling 
procedure. To a round bottom flask charged with a magnetic stirrer were added N-Fmoc-Phe-OH 
(71) (8.52 g, 22 mmol), HClH-L-Ser-OMe (70) (3.1 g, 20 mmol), O-benzotriazole-N,N,N',N'-
tetramethyluroniumhexafluorophosphate (HBTU) (9.8 g,  26 mmol), and anhydrous DCM (220 mL) 
at room temperature and the mixture was cooled to 0 
0
C. N,N-diisopropylethylamine (17.4 mL, 100 
mmol), was added to the mixture at 0 
0
C under a nitrogen atmosphere and stirred at room 
temperature for 24 h. The mixture was quenched with 1 M HCl, subsequently treated with saturated 
NaHCO3, and brine.  The organic layer was collected and dried over magnesium sulfate, and the 
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solution filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography on silica gel with 20% ethyl acetate in hexane as eluent to afford 69, a white solid 
(85% yield). m. p. 188 
0
C, 
1
H NMR (500 MHz, DMSO-d6) δ 8.47 (d, J = 7.6 Hz, 1H; NH), 7.88 (d, 
J = 7.6 Hz, 2H; 2x HAr), 7.73 – 7.58 (m, 3H; 3x HAr), 7.47 – 7.08 (m, 8H; 8x HAr), 5.14 (t, J = 5.3 
Hz, 1H; NH), 4.50 – 4.32 (m, 2H; CHCH2O, CHCH2Phe), 4.22 – 4.00 (m, 3H; CHCH2OFMOC, 
CHCH2OH SERINE), 3.77 (dt, J = 11.3, 5.4 Hz, 1H; CHCH2OH  ), 3.64 (s, 4H; CHCH2OH, 
OCH3), 3.14 – 2.97 (m, 1H; CH2Phe), 2.77 (t, J = 12.3 Hz, 1H; CH2Phe). 
13
C NMR (126 MHz, 
DMSO-d6) δ 172.45; (CO)OCH3, 171.45; CONH, 156.25; OCONH , 144.22-144.18; CHAr , 
141.11-141.09; CHAr , 138.65; CHAr, 129.77; CHAr, 128.45; CHAr , 128.08; CHAr  , 127.51; CHAr , 
126.66; CHAr , 125.82-125.73; CHAr , 120.54; CHAr , 66.10; CHCH2O, 61.68; CHCH2OH , 56.31; 
CHCH2OH , 55.19; OCH3, 52.37; CHCH2Phe , 46.99; CHCH2O , 37.91; CHCH2Phe . 
 
3.3.2.  Synthesis of N-Fmoc-L-Phe-L-Oxazoline-OMe (72) 
To a solution of compound 69 (1.95 g, 4 mmol) in THF (40 mL) was added 1.04 g (4.4 
mmol) of Burgess reagent. The mixture was refluxed for 2.5 h. The solvent was removed in vacuo. 
The residue was purified using “Dry Column” Flash Chromatography or Dry Column Vacuum 
Chromatography. The compound was eluted through neutral silica gel with 30% and 40% diethyl 
ether in hexane, respectively, to afford compound N-Fmoc-L-Phe-L-Oxazoline-OMe (72)  (1.33 g, 
2.8 mmol, 71%) as a white solid.
 1
H NMR (500 MHz, Chloroform-d) δ 7.80 (d, J = 7.4 Hz, 2H; 2x 
HAr), 7.60 (q, J = 7.6, 6.0 Hz, 2H; 2x HAr), 7.43 (q, J = 6.7, 6.1 Hz, 2H; 2x HAr), 7.38 – 7.18 (m, 5H; 
5x HAr), 7.12 (d, J = 7.2 Hz, 2H; 2x HAr), 5.46 (d, J = 8.7 Hz, 1H; NH), 4.82 (q, J = 7.2, 6.6 Hz, 1H; 
CH2-oxazoline), 4.79 – 4.70 (m, 1H; CH2-oxazoline), 4.68 – 4.58 (m, 1H; CH-oxazoline), 4.50 (td, 
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J = 11.0, 10.4, 7.0 Hz, 2H; OCH2CH), 4.35 (dd, J = 10.8, 7.1 Hz, 1H; CHCH2Phe), 4.23 (t, J = 7.3 
Hz, 1H; OCH2CH), 3.78 (d, J = 5.4 Hz, 3H; OCH3), 3.19 (dd, J = 13.8, 5.9 Hz, 1H; CH2Phe), 3.12 
(dd, J = 13.9, 5.9 Hz, 1H; CH2Phe). 
13
C NMR (126 MHz, CDCl3) δ 170.83; (CO)OCH3 , 168.95; 
OC=N , 155.47; OCONH , 143.76; CHAr , 141.33; CHAr , 135.49; CHAr , 129.65; CHAr , 128.41; 
CHAr , 127.71; CHAr , 127.07; CHAr , 125.10; CHAr ,119.98; CHAr , 70.14; OCH2CH , 
67.77;OCH2CH , 66.88; CHCH2O , 52.74; OCH3 , 50.12; CHCH2Phe, 47.19 ; CHCH2O, 38.70; 
CHCH2Phe . 
 
3.3.3.  Synthesis of N-Fmoc-L-Phe-L-Oxazole-OMe (68) 
To the oxazoline, 72, (3.3 g, 7.07 mmol) in a 100 mL round-bottomed flask, were added 
CuBr (1.104 g, 1.10 mmol) and Cu(OAc)2 (1.39 g, 1.10 mmol). The flask was evacuated and then 
filled with argon. The evacuation/argon addition was repeated twice. Benzene (44.1 mL) was added 
to the flask with a syringe and stirring initiated. The reaction mixture was heated to 60°C and tert-
butyl perbenzoate (1.5 ml, 1.50 mmol) was added gradually over 15 min. The reaction mixture was 
then refluxed for 8.5 h. After cooling to room temperature, ethyl acetate (50 mL) was added and the 
mixture was washed with 10% NH4OH solution to remove all the copper salts. The aqueous layer 
was extracted with 3 x 50 mL portions of ethyl acetate.  The combined organic extracts were dried 
over MgSO4 and the crude product, obtained after concentration under vacuum, was subjected to 
flash column chromatography on SiO2 [hexane /ethyl acetate; (60:40)]. This produced 2.22 g (68% 
yield) of 68, a white solid with a m. p. of 146
0
C. 
1
H NMR (500 MHz, Chloroform-d) δ 8.16 (s, 1H; 
OCH=C), 7.79 (d, J = 7.6 Hz, 2H; 2x HAr), 7.58 (dd, J = 10.5, 7.6 Hz, 2H; 2x HAr), 7.43 (t, J = 7.5 
Hz, 2H; 2x HAr), 7.39 – 7.30 (m, 3H; 3x HAr), 7.30 – 7.22 (m, 2H; 2x HAr), 7.08 – 6.99 (m, 2H; 2x 
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HAr), 5.56 (d, J = 8.8 Hz, 1H; NH), 5.30 (q, J = 7.3 Hz, 1H; CHCH2Phe), 4.45 (td, J = 10.8, 7.0 Hz, 
1H; CH2), 4.36 (dd, J = 10.7, 6.9 Hz, 1H; CH2), 4.21 (t, J = 7.1 Hz, 1H; CH), 3.94 (s, 3H; OCH3), 
3.33 – 3.23 (m, 2H; CHCH2Phe). 
13
C NMR (126 MHz, Chloroform-d) δ 164.27; (CO)OCH3, 
161.41; OC=N, 155.47; OCONH , 144.02; CHAr , 143.70; OCH=C , 141.31; CHAr, 135.26; CHAr , 
133.32; NC(CO), 129.24; CHAr  , 128.71; CHAr , 127.74; CHAr , 127.26; CHAr , 127.08; CHAr , 
125.08; CHAr , 67.13; CHCH2O , 52.34; OCH3, 50.60; CHCH2Phe , 47.11; CHCH2O  , 40.18; 
CHCH2Phe. 
 
3.3.4.  Synthesis of HO-Oxazole-L-Phe- NHFmoc (66) 
The reagent system, AlCl3 (0.350 g, 9 mmol)/N,N-dimethylaniline (15 mmol), was added to a 
suspension of 68 (0.3068 g, 0.3 mmol)  in dry DCM (3 mL). The resulting mixture was refluxed for 
6 h. The conversion of 68 was monitored by TLC (DCM/methanol, 90:10). HCl (1 N) was then 
added to acidify the solution (pH2). The product was extracted with DCM (4 x 10 mL). The 
combined organic layers were washed with brine, then dried over MgSO4 and evaporated to dryness 
to give a crude reaction product that was purified by column chromatography on SiO2 
(DCM/methanol; 95:5) to obtain the pure compound, 66, as a white solid (10% yield). 
1
H NMR 
(500 MHz, DMSO-d6) δ 8.70 (s, 1H; OCH=C), 8.20 (d, J = 8.4 Hz, 1H; HAr), 7.88 (d, J = 7.7 Hz, 
2H; 2x HAr), 7.62 (d, J = 6.3 Hz, 2H; 2x HAr), 7.41 (t, J = 7.5 Hz, 3H; 3x HAr), 7.35 – 7.28 (m, 3H; 
3x HAr), 7.27 (d, J = 4.7 Hz, 4H; 4xHAr), 6.72 (d, J = 8.2 Hz, 2H, 2xHAr ), 6.64 (t, J = 7.2 Hz, 1H; 
NH), 4.95 (d, J = 7.6 Hz, 1H; CHCH2Phe), 3.27 (dd, J = 13.7, 5.7 Hz, 2H; CHCH2Phe). 
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3.3.5.  Synthesis of N-Boc-L-Phe-L-Ser-OMe (82) 
To a solution of N-Boc-L-Phe-OH (84) (7.9 g, 30 mmol) in DCM (0.1 M, 300 mL) was 
added HClH-Ser-OMe (83) (4.6 g, 30 mmol), and HBTU (13.6 g, 36 mmol) at room temperature. 
The mixture was cooled to 0°C before adding DIEPA (16.6 mL, 96 mmol). The mixture was then 
stirred at room temperature under an atmosphere of nitrogen for 16 h. The mixture was then diluted 
with DCM and poured into 0.5 N NaHSO4. The aqueous layer was extracted twice with DCM. The 
organic layer was washed with saturated aqueous NaHCO3, H2O, and brine, dried over MgSO4 and 
filtered. The filtrate was concentrated in vacuo. The product was purified by column 
chromatography on flash silica gel with 50% ethyl acetate in hexane as eluent to afford compound 
82 in 67% yield. (m. p. 85 
0
C).  
1
H NMR (500 MHz, Chloroform-d) δ 7.36 – 7.24 (m, 4H; 4x HAr), 
7.23 (m, 1H; 1x HAr), 6.87 (d, J = 7.3 Hz, 1H; NH-Ser), 5.09 (s, 1H; NH-Phe), 4.61 (d, J = 6.2 Hz, 
1H; CHCH2Phe), 4.36 (q, J = 7.2 Hz, 1H; CHCH2OH), 3.97 (d, J = 11.9 Hz, 1H; CHCH2OH), 3.91 
(d, J = 11.4 Hz, 1H; CHCH2OH), 3.78 (s, 3H; OCH3), 3.11 (qd, J = 14.0, 6.9 Hz, 2H; CHCH2Phe), 
2.69(s, 1H; CHCH2OH), 1.42 (s, 9H; C(CH3)3OCO). 
13
C NMR (126 MHz, CDCl3) δ 171.64; 
(CO)OCH3, 170.49; CONH, 155.7; C(CH3)3OCO, 136.45; CHAr, 129.30; CHAr, 128.66; CHAr, 
127.01; CHAr, 80.57; C(CH3)3OCO,[77.28, 77.02, 76.77], 62.76; CHCH2OH, 56.0; CHCH2OH, 
54.94; CHCH2Phe, 52.70; OCH3, 38.04;CHCH2Phe, 28.23; C(CH3)3OCO.  
 
3.3.6. Synthesis of N-Boc-L-Phe-Oxazoline-OMe (85) 
Method (A): 
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To a solution of 3.7 g compound 82 (10 mmol) in 101 mL of THF was added 2.6 g of 
Burgess reagent (11.1 mmol). The mixture was refluxed for 2.5 h at which point the solvent was 
removed in vacuo. The residue was filtered through a dry column of natural silica gel, and the 
compounds was eluted first with 30% and then with 40% ethyl acetate in hexane to afford 2.9 g of 
85 (84%) as a yellow syrup. 
1
H NMR (500 MHz, Chloroform-d) δ 7.27 (q, J = 10.5, 8.6 Hz, 3H; 
3xHAr), 7.13 (d, J = 7.3 Hz, 2H; 2x HAr), 5.17 (d, J = 8.4 Hz, 1H; NH-Phe), 4.73 (t, J = 8.9 Hz, 2H; 
OCH2CH-oxaz), 4.60 (t, J = 8.3 Hz, 1H; OCH2CH-oxaz), 4.46 (dd, J = 10.6, 8.6 Hz, 1H; 
CHCH2Phe), 3.76 (s, 3H; OCH3), 3.16 (dd, J = 14.0, 5.8 Hz, 1H; CHCH2Phe), 3.06 (dd, J = 13.9, 
5.6 Hz, 1H; CHCH2Phe), 1.42 (s, 9H; C(CH3)3OCO). 
13
C NMR (126 MHz, CDCl3) δ 170.88; 
(CO)OCH3, 169.28; OC=N, 154.85; OCONH, 135.79; CHAr , 129.61; CHAr , 129.45; CHAr, 128.29; 
CHAr, 126.81;CHAr, 79.75;C(CH3)3OCO, [77.30, 77.25, 77.04, 76.79], 69.99; OCH2CH, 67.81; 
OCH2CH, 52.25; OCH3, 49.65; CHCH2Phe, 38.87; CHCH2Phe, 28.29; C(CH3)3OCO. 
Method (B): 
 A solution of 1.95 g of 82 (4 mmol) in 40 mL DCM was cooled to -78 
0
C. DAST (0.50 mL, 
5.2 mmol) was added under a nitrogen atmosphere at a rate of 0.1 mL/ min.  After being stirred for 
1.5 h, anhydrous K2CO3 (1.1 g. 8 mmol) was added and the reaction mixture was stirred at -78 
0
C 
for 1 h.  Then, the reaction mixture was stirred for an additional 1.5 h at room temperature. The 
organic solution was poured into saturated aqueous sodium bicarbonate and extracted twice with 
DCM. The organic layers were combined, dried over magnesium sulfate, filtered, and concentrated 
in vacuo. The product was purified by column chromatography on flash silica gel with 70% ethyl 
acetate in hexane as an eluent to give the oxazoline, 85 (88%) as an oil. 
 
 
 
 
 
105 
3.3.7.  Synthesis of N-Boc-L-Phe-Oxazole-OMe (81) 
A solution of oxazoline (85) (2.2 g, 6.5 mmol) dissolved in 65 mL of DCM was cooled in an 
ice bath. DBU (1.95 mL, 13 mmol) was added dropwise under a nitrogen atmosphere. BrCCl3 (1.28 
mL, 13 mmol) was slowly added to the mixture so as to maintain the temperature at 0 
0
C. The 
reaction mixture attained room temperature as it was left to stir overnight. The mixture was poured 
into aqueous saturated NHCl4. The product was extracted with EtOAc. The combined organic 
phases were washed with brine, dried over MgSO4 and taken to dryness. The residue was purified 
by column chromatography on flash silica gel with 30% ethyl acetate in hexane as an eluent 
yielding 2.1 g (91% yield) of 81 as a white powder (m. p. 109 
0
C). 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.15 (d, J = 8.8 Hz, 1H; OCH=C(oxaz)), 7.43 – 7.19 (m, 3H; 3x HAr), 7.06 (s, 2H; 
2x HAr), 5.39 – 5.18 (m, 2H; CHCH2Phe, NH-Phe), 3.93 (s, J = 3.5 Hz, 3H; OCH3), 3.26 (d, J = 
15.6 Hz, 2H; CHCH2Phe), 1.43 (s, J = 7.8 Hz, 9H; C(CH3)3OCO).
 13
C NMR (126 MHz, CDCl3) δ 
164.75; (CO)OCH3, 161.47; C=N,154.84; O(CO)NH, 143.86;OCH=C, 135.58;CH-Ar, 133.27; 
OCH=C, 129.23; CHAr, 128.59; CHAr, 127.07; CHAr, 80.20; C(CH3)3OCO, 52.23; OCH3, 50.14; 
CHCH2Phe, 40.37; CHCH2Phe, 28.24; C(CH3)3OCO. 
 
3.3.8.  Synthesis of HClH2N-L-Phe-Oxazole-OMe (80) 
 Compound 81 (2.9 g, 8.3 mmol) was dissolved in 83 mL of THF. The solution was added in 
one portion to 4 mL of a 4 M HCl/dioxane solution cooled to 0 
0
C and kept under a nitrogen 
atmosphere. The ice bath was removed after 30 min and stirring continued at room temperature for 
4 h. The mixture was concentrated in vacuo. The residue was washed with dry diethyl ether and 
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collected by filtration to provide 80 (1.4 g), a pale yellow solid used in the next step without further 
purification (m. p. 205 
0
C). 
1
H NMR (500 MHz, DMSO-d6) δ 9.17 (s, 2H; NH2-Phe), 8.93 (s, 1H; 
OCH=C(oxaz)), 7.26 (dd, J = 14.3, 7.0 Hz, 3H; 3xHAr), 7.12 (d, J = 7.1 Hz, 2H; 2x HAr), 4.88 (dd, J 
= 9.7, 5.2 Hz, 1H; CHCH2Phe), 3.82 (s, 3H; OCH3), 3.44 (dd, J = 13.5, 5.1 Hz, 1H; CHCH2Phe), 
3.24 (dd, J = 13.5, 9.7 Hz, 1H; CHCH2Phe). 
13C NMR (126 MHz, DMSO) δ 161.12; (CO)OCH3, 
160.93; C=N, 146.80; OCH=C, 135.00; OCH=C, 132.9; CHAr, 129.59; CHAr, 129.08; CHAr, 127.74; 
CHAr, 66.82; 52.46; OCH3, 49.38; CHCH2Phe, 37.91; CHCH2Phe. 
 
3.3.9.  Synthesis of N-Boc-Phe-Oxazole-OH (79) 
A solution of LiOHH2O (2M, 31 mL) was added dropwise over a 10 min period to a 
solution of 2.1 g of 81 (6.2 mmol) in 62 mL of THF/H2O (1:1) and the mixture was stirred at 0°C 
for 1.5 h under a nitrogen atmosphere. The mixture was allowed to warm to room temperature and 
to stir for an additional 2 h. The solution was concentrated to half its volume. The resulting aqueous 
phase was acidified with 1 M HCl to pH2 at 0 °C. The aqueous phase was repeatedly extracted 
with EtOAc; the organic layers were combined, washed with brine, dried over MgSO4, and filtered. 
The filtrate was concentrated in vacuo. The crude product (1.63 g, m. p. 120 
0
C) was used in the 
next step without further purification. 
1
H NMR (500 MHz, Chloroform-d) δ 8.23 (s, 1H; 
OCH=C(oxaz)), 7.28 (d, J = 7.5 Hz, 3H; 3xHAr), 7.10 (s, 2H; 2xHAr), 5.86 (s, 1H; NH-Phe), 5.27 (s, 
1H; CHCH2Phe), 3.26 (d, J = 6.9 Hz, 2H; CHCH2Phe), 1.41 (s, 9H; C(CH3)3OCO ). 
13
C NMR (126 
MHz, CDCl3) δ 165.75; (CO)OH, 163.86; C=N, 155.10; O(CO)NH , 144.73; OCH=C, 135.55; 
CHAr, 132.86; OCH=C, 129.22; CHAr, 128.64; CHAr, 127.13; CHAr, 80.27;C(CH3)3OCO, [77.26, 
77.01, 76.75] , 50.29; CHCH2Phe, 40.35; CHCH2Phe, 28.25; C(CH3)3OCO. 
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3.3.10. Synthesis of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-OMe 
(78) 
To a solution of 1.06 g of 79 (3.9 mmol) in 39 mL of DCM was added 0.66 g of 80 (3.9 
mmol), and 1.77 g of HBTU (4.6 mmol). Once cooled to 0°C, 22.1 mL of DIEPA (12.4 mmol) was 
added to the reaction mixture which was subsequently stirred at room temperature under a nitrogen 
atmosphere. The following day the reaction mixture was diluted with DCM and poured into 0.5 N 
NaHSO4. The aqueous layer was extracted twice with DCM. The organic layer was washed with 
saturated aqueous NaHCO3, H2O, and brine, dried over MgSO4 and filtered. The filtrate was 
concentrated in vacuo. The product was purified by column chromatography on flash silica gel with 
50% ethyl acetate in hexane furnishing 78 in 75% yield (m. p. 155 
0
C) 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.13 (s, 1H;OCH=C(oxaz)), 8.08 (s, 1H;OCH=C(oxaz)), 7.49 (d, J = 8.8 Hz, 1H; 
NH-Phe), 7.27 (d, J = 16.8 Hz, 6H; 6xHAr), 7.11 (d, J = 6.8 Hz, 2H; 2xHAr), 7.04 (d, J = 7.0 Hz, 2H; 
2xHAr), 5.67 (q, J = 7.5 Hz, 1H; NH-Phe), 5.16 (d, J = 22.0 Hz, 2H; CHCH2Phe, CHCH2Phe), 3.93 
(s, 3H; OCH3), 3.38 (dd, J = 7.1, 3.7 Hz, 2H; CHCH2Phe), 3.26 – 3.14 (m, 2H; CHCH2Phe), 1.45 
(s, 9H; C(CH3)3OCO). 
13
C NMR (126 MHz, CDCl3) δ 164.75; (CO)OCH3, 163.52;C=N, 
161.39;C=N, 159.84; CONH, 154.79; O(CO)NH, 143.88; OCH=C, 141.38; OCH=C,135.62; CHAr, 
135.37; CHAr, 133.44; 2x OCH=C, 129.23; 2xCHAr, 128.55; 2xCHAr, 127.22;2x CHAr, 80.31; 
C(CH3)3OCO, 52.23; OCH3, 49.91; CHCH2Phe, 48.32; CHCH2Phe, 40.07; CHCH2Phe, 38.80; 
CHCH2Phe, 28.29; C(CH3)3OCO. 
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3.3.11.  Synthesis of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-Phe-OH 
(76) 
A solution of methyl ester, 78 (0.97 g, 1.7 mmol), in 8.5mL of THF/H2O (1:1) was added 
dropwise to 17 mL of a 2 M LiOHH2O solution over a 10 min period at 0°C under a nitrogen 
atmosphere. The mixture was stirred at 0 °C for 1.5 h. At this point, the mixture was allowed to 
warm to room temperature and was stirred for additional 2 h. TLC was used to monitor the reaction 
until the starting material had been consumed. The solution was concentrated to one-half volume. 
The resulting aqueous phase was acidified with 1 M HCl to a pH2 at 0°C. The aqueous phase was 
extracted with several portions of ethyl acetate; the organic layers were combined, washed with 
brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo resulting in 1.32 g of 
crude 76 (m. p. 191 
0
C). 
1
H NMR (500 MHz, DMSO-d6) δ 8.79 (d, J = 8.6 Hz, 1H;NH-Phe), 8.70 
(s, 1H; OCH=C (oxaz)), 8.54 (s, 1H; OCH=C (oxaz)), 7.61 (d, J = 8.4 Hz, 1H; NH-Phe), 7.26 (d, J 
= 4.1 Hz, 10H; 10xHAr), 5.45 (s, 1H; CHCH2Phe), 4.90 (s, 1H; CHCH2Phe), 3.41 (d, J = 5.2 Hz, 
2H; CHCH2Phe), 3.24 (m, 1H; CHCH2Phe), 3.08 (d, J = 13.1 Hz, 1H; CHCH2Phe), 1.30 (s, 9H; 
C(CH3)3OCO). 
13C NMR (126 MHz, DMSO) δ 164.37; (CO)OH, C=N, 163.52; C=N, 160.16; 
CONH, 155.41; O(CO)NH, 142.74; 2x OCH=C, 137.72; 2x CHAr, 135.65; 2x OCH=C, 129.60; 
2xCHAr, 128.68; 2x CHAr, 126.99; 2x CHAr, 78.84; C(CH3)3OCO, 50.44; CHCH2Phe, 48.41; 
CHCH2Phe, 31.42; 2x CHCH2Phe, 28.56; C(CH3)3OCO. 
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3.3.12. Synthesis of HClNH2-L-Phe-Oxazole-L-Phe-Oxazole-OMe  
(77) 
The Boc-protected compound, 78, (0.965 mmol) was dissolved in 9.7 mL of THF and added 
in one portion to 4 mL of a 4M HCl/dioxane solution cooled to 0°C under a N2 atmosphere. The ice 
bath was removed after 30 min and stirring continued at room temperature. The TLC analysis 
indicated that the reaction was complete after 4 h. The mixture was concentrated in vacuo. The 
residue was washed with dry diethyl ether and collected by filtration to provide 0.6920 g of 77 as a 
pale yellow solid (m. p. 120 
0
C) that was used in the next step without further purification. 
1
H NMR 
(500 MHz, DMSO-d6) δ 8.87 – 8.80 (m, 2H; NH2-Phe), 8.69 (s, 3H; 2x OCH=C(oxaz),1x NH-Phe), 
7.44 – 7.04 (m, 10H, ; 10x HAr), 5.45 (s,1H; CHCH2Phe), 4.78 (s, 1H; CHCH2Phe), 3.82 (s, 3H; 
OCH3), 3.39 (s, 2H; CHCH2Phe), 3.29 (s, 2H; CHCH2Phe). 
13
C NMR (126 MHz, DMSO) δ164.11; 
(CO)OCH3, 163.52; C=N, 160.16; C=N, CONH, 145.41; OCH=C, 142.74; OCH=C, 137.72; 2x 
CHAr, 135.65; 2x OCH=C, 129.66; 2x CHAr, 129.70; 2x CHAr, 128.70; 2x CHAr, 127.74; 2x CHAr, 
52.46; OCH3. 52.31; 2x CHCH2Phe, 39.50; 2x CHCH2Phe. 
 
3.3.13. Synthesis of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe-
Oxazole-L-Phe-Oxazole-OMe (75)  
A solution of 696 mg of 76 (1.5 mmol) in DCM was added to 375 mg of 77 (1.5 mmol), 340 
mg of HOBt (1.8 mmol), and 275 mg of EDC (1.5 mmol) at room temperature. Once cooled to 0°C, 
0.65 mL of DIEPA (1.8 mmol) was added under a nitrogen atmosphere and the mixture was stirred 
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for 24 h. The reaction mixture was diluted twice with DCM and poured into 0.5 N NaHSO4. The 
aqueous layer was extracted with DCM. The organic layer was washed sequentially with saturated 
aqueous NaHCO3, H2O, and brine, dried over MgSO4, and filtered. The filtrate was concentered in 
vacuo. The product was purified by column chromatography on flash silica gel with 50% ethyl 
acetate in hexane giving 986 mg of 75 (67% yield) as a white solid (m. p. 160 
0
C). 
1
H NMR (500 
MHz, Chloroform-d) δ 8.12 (d, J = 7.4 Hz, 3H; 3x OCH=C(oxaz)), 8.08 (s, 1H; OCH=C(oxaz)), 
7.52 (s, 1H; NH-Phe), 7.28 (s, 15H; 15x HAr), 7.12 (d, J = 8.6 Hz, 5H; 5xHAr), 7.02 (s, 2H; 2x NH-
Phe), 5.65 (s, 2H; CHCH2Phe), 5.18 (s, 1H; CHCH2Phe), 5.06 (s, 1H; NH-Phe), 3.90 (s, 3H; 
OCH3), 3.45 – 3.16 (m, 8H; 4x CHCH2Phe), 1.42 (s, 9H; C(CH3)3OCO). 
13
C NMR (126 MHz, 
CDCl3) δ 164.02; (CO)OCH3, 163.52-162.67; 2x C=N, 162.61; C=N, 161.39; C=N, 159.79; 
3xCONH, 159.76; O(CO)NH, 143.92;OCH=C, 141.71; OCH=C, 141.60; OCH=C, 141.53; 
OCH=C, 135.52; OCH=C, 135.47; OCH=C, 135.42; OCH=C, 135.37, OCH=C, 133.40; 2x CHAr, 
129.26; 2x CHAr, 129.24; 2x CHAr, 129.21; 2x CHAr, 128.70; 2x CHAr, 128.66; 2x CHAr, 128.59; 2x 
CHAr, 127.24; 2x CHAr, 127.14; 2x CHAr, 80.42; C(CH3)3OCO, 52.22; OCH3, 48.34, 2x 
CHCH2Phe, 48.11; 2x CHCH2Phe, 39.63; CHCH2Phe, 39.52; CHCH2Phe, 31.58; CHCH2Phe, 
30.92; CHCH2Phe, 28.26; C(CH3)3OCO. 
 
3.3.14. Synthesis of HO-Oxazole-L-Phe-Oxazole-L-Phe-Oxazole-L-
Phe Oxazole-L-Phe-NH2 (74) 
10 mL of LiOHH2O (2 M) was added dropwise, over a 10 min period, to solution of 986 mg 
of 75 (0.996 mmol) in 10 mL of THF/H2O (1:1). The mixture was stirred at 0°C for 1.5 h under N2. 
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The mixture was allowed to warm to room temperature and stirred for an additional 2 h. The 
solution was concentrated to one-half volume. The resulting aqueous phase was acidified to pH~ 2 
with 1 M HCl at 0°C. The aqueous phase was repeatedly extracted with ethyl acetate; the organic 
layers were combined, washed with brine, dried over MgSO4, and filtered. The filtrate was 
concentrated in vacuo. The crude acid was dissolved in 9 mL of THF. A 4 M HCl/dioxane (4 mL) 
solution, cooled to 0°C, was added in one portion under a nitrogen atmosphere. The ice bath was 
removed after 30 min and stirring continued at room temperature for 4 h. The mixture was 
concentrated in vacuo. The residue was then washed with dry diethyl ether and collected by 
filtration to provide 724 mg of 74 as a yellow solid (m. p. 170 
0
C) used without further purification. 
1
H NMR (500 MHz, Methanol-d4) δ 8.42 (d, J = 6.2 Hz, 2H; 2x OCH=C(oxaz)), 8.33 (d, J = 12.6 
Hz, 2H; 2x OCH=C(oxaz)), 7.28 (dd, J = 23.5, 6.8 Hz, 12H; 12xHAr), 7.22 (s, 8H; 8xHAr), 5.57 (d, 
J = 7.8 Hz, 3H; 3x CHCH2Phe),4.94 (s, 1H; CHCH2Phe), 3.47 (s, 4H; CHCH2Phe), 3.38 (s, 4H; 4x 
CHCH2Phe).
13C NMR (126 MHz, CDCl3) δ 163.33; CONH, 160.74; C=N, 159.59; CONH, 144.33; 
C=N, 143.14; 2xOCH=C, 142.16; CHAr, 136.2; 2xOCH=C, 135.35; 4xOCH=C, 133.78; C=N , 
128.93; 2xCHAr, 128.92; 2x CHAr, 128.70; 2x CHAr, 128.18; 2x CHAr, 127.53; 5x CHAr, 126.64; 
C=N, 49.75; 2x CHCH2Phe, 48.62; 2x CHCH2Phe, 38.23; CHCH2Phe, 38.06; 3x CHCH2Phe. 
3.3.15.   Synthesis of Macrocycle Oxazole-L-Phe-Oxazole-L-Phe- 
Oxazole-L-Phe-Oxazole-L-Phe (55) 
A solution of 458 mg of PyOxP (0.86 mmol) and 0.60 mL of DIPEA (3.47 mmol) in 794 
mL of DMF was added dropwise at room temperature, under a nitrogen atmosphere, to 724 mg of 
74 (0.794 mmol). After being stirred for 3 days, DMF was removed under reduced pressure. The 
mixture was diluted with DCM and was poured into 1 N NaHSO4. The aqueous layer was extracted 
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twice with DCM. The organic layers were washed with saturated aqueous NaHCO3 and brine, dried 
over MgSO4, and filtered. The filtrate was concentrated in vacuo. The crude product was 
precipitated with diethyl ether. The residue was purified by trituration with hot hexane resulting in 
400 mg of macrocycle, 55 (45% yield, m. p. 140 
0
C). 
1
H NMR (500 MHz, Chloroform-d) δ 8.13 (s, 
4H; 4x OCH=C(oxaz)), 7.35 – 7.27 (m, 16H; 4xNH-Phe, 12xHAr), 7.16 – 7.11 (m, 4H; 4xHAr), 5.75 
(q, J = 6.6 Hz, 4H; 4xCHCH2Phe), 3.45 – 3.32 (m, 8H; 4x CHCH2Phe). 
13
C NMR (126 MHz, 
CDCl3) δ 163.03; 4xCONH, 159.33; 4x N=CO, 141.87; 4x OCH=C, 153.6; 4x CHAr, 135.53; 4x 
OCH=C, 129.32; 4x CHAr, 128.69; 4x CHAr, 127.36; 4x CHAr, , 47.50; 4x CHCH2Phe, 40.28; 4x 
CHCH2Phe. 
 
3.3.16. SPPS of Macrocycle Oxazole-L-Phe-Oxazole-L-Phe- 
Oxazole-L-Phe-Oxazole-L-Phe (55) 
3.3.16.1. Loading N-Boc-L-Phe-Oxa-OH (79) onto the Oxime resin 
The Oxime resin (100-200 mesh, 0.61 mmol/g, 164 mg) was initially washed with DMF (5x 
3 mL) and DCM (5x 3 mL). Next it was allowed to swell in DCM for 0.5 h and then with DMF for 
1 h. After the solvent was decanted from the resin, N-Boc-L-Phe- Oxa-OH (79) (0.265 g, 0.24 
mmol), HBTU (0.303 g, 0.24 mmol), and DIPEA (0.209 mL, 0.36 mmol) dissolved in 3 mL of 
DMF was added and the mixture was shaken for 12 h. After 12 h, the solution was drained and the 
resin was washed exhaustively with DMF (5x 5mL), DCM (5x 5mL), and DMF (1x 5 mL). 
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3.3.16.2. Acetylation of the N-Boc-L-Phe-Oxa-OH-loaded resin 
Acetylation was carried out by adding 0.64 mL of acetic anhydride (7 mmol) and 0.5 mL of 
DIPEA (3.9 mmol) in 1.5 mL of DMF to the N-Boc-L-Phe- Oxa-OH-loaded resin. After shaking the 
mixture for 1 h, the resin was rinsed with DMF (5x 5 mL), DCM (5x, 5 mL), and DMF (1x 5 mL). 
 
3.3.16.3. Deprotection of N-Boc group of acetylated N-Boc-L-Phe-
Oxa-OH-loaded resin 
The N-Boc group was removed by adding 3 mL of a 25% TFA/DCM solution to the resin. 
After agitating the mixture for 1 min, the liquid was decanted and an additional 3 mL of TFA/DCM 
solution was added to the resin. After 0.5 h of agitation, the liquid was decanted and the resin was 
treated with 3 mL of 5% DIPEA in DMF to remove excess TFA. 
3.3.16.4. Procedure used to couple amino acids to the NH2-L-Phe-
Oxa-Oxime resin (90) 
The second coupling reaction was performed using fragment 89 (0.18 g, 0.12 mmol) in the 
presence of HBTU (0.037 g, 0.12 mmol), HOBt (0.13 g, 0.12 mmol), and DIPEA (0.025 mL, 0.18 
mmol) in 3 mL of DMF. After agitating the reaction mixture for 3 h, a Kaiser ninhydrin test 
indicated the coupling was complete. The liquid was decanted and the resin was washed with DMF 
(5x 5mL), DCM (5x 5mL), and DMF (1x, 5 mL).  
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The N-Boc group was removed with a solution of TFA in DCM using the procedure 
outlined above. The symmetric anhydride of N-Boc-L-Phe-Oxa-OH (79) in DMF was subsequently 
coupled to the resin in the presence of DIPEA (0.05 mL, 0.18 mmol). After 3 h, the product was 
recovered and the N-Boc group removed as outlined above. This was repeated until the desired 
number of oxazole units was obtained. 
 
3.3.16.5. Cyclization-Cleavage 
The cyclization-cleavage reactions were carried out by shaking the peptidyl resin, 86, in 
DCM (10 mL) in the presence of 6% acetic acid at room temperature for 3 days. The resin was 
filtered from the solution containing the cyclic peptide. The resin was washed with DCM (3X 
5mL). The filtrate was combined with the cyclic peptide containing solution above and was 
concentrated in vacuo. The residue was washed with ice cold water, 0.1 N HCl, 5% NaHCO3, and 
brine. The organic layer was evaporated and the crude product, 55, was purified by reverse phase 
HPLC. This procedure gave a 20% yield of 55. 
 
 
3.4. Method Used to Study the Copper(II)-Macrocyclic Tetraoxazole 
(55) Complexation 
Preparation of the stock solutions: 
A stock solution of 55 (6 mM) was prepared by adding methanol to 23 mg of 55 in a 10 
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mL volumetric flask. To prepare a 37.5 mM stock solution of copper(II) triflate, 138 mg of the 
compound were added to a 10 mL volumetric flask, and diluted with methanol to the mark. A 75 
mM stock solution of tetrabutylammonium ethoxide was prepared by diluting 300 L of the 
compound (20% w/v) in a 10 mL volumetric flask with methanol.  
 
UV-Vis titration of the tetraoxazole macrocycle (55) with Cu(II): 
Spectrophotometric titrations were performed in methanol at 25 C in a 1 cm3 quartz 
cuvette. The spectrophotometer (Cary 60, Agilent) was set to 0.0 absorbance from 300 to 1000 
nm using methanol as a blank. A volume of 250 L of 55 (6 mM) was diluted with 750 L 
methanol to make a final concentration of 1.5 mM, and the absorbance of the sample between 
300 nm and 1000 nm was recorded. The Cu(II)-containing samples were prepared in the same 
manner, except for the inclusion of copper(II) triflate (ranging from 0.25 molar eq to 4 molar eq). 
All samples were incubated for 2-3 min prior to measurement of the UV–Vis spectra. 
 
UV-Vis titration of the Cu
2+
-tetraoxazole macrocycle (55) complex 
with tetrabutylammonium ethoxide 
In a final volume of 1 mL, 250 L of 55 (6 mM) were mixed with 200 L of the 
copper(II) triflate stock solution (37.5 mM) and 550 L methanol to prepare the copper complex 
(2:1 metal:macrocycle ratio). The mixture was incubated for 5 min, transferred to a cuvette, and 
the UV-Vis spectrum was recorded as outlined above. Samples containing various concentrations 
of tetrabutylammonium ethoxide (using a 75 mM stock solution) were prepared following the 
protocol described above, except for the inclusion of the base. Each sample (final volume of 1 
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mL) was incubated in the presence of the base for 2-3 min before UV-Vis spectra were recorded 
at room temperature.  
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Appendix S 1: 
1
H NMR Spectrum of N-Fmoc-L-Phe-L-Ser-OMe (69) in DMSO-d6 
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Appendix S 2: 
13
C NMR Spectrum of N-Fmoc-L-Phe-L-Ser-OMe (69) in DMSO-d6 for an enlargement of the 110-160 ppm range see 
next page) 
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Appendix S 3: COSY NMR Spectrum of N-Fmoc-L-Phe-L-Ser-OMe (69) in DMSO-d6 
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Appendix S 4: DEPT 90 NMR Spectrum of N-Fmoc-L-Phe-L-Ser-OMe (69) in DMSO-d6 
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Appendix S 5: DEPT 90 NMR Spectrum of N-Fmoc-L-Phe-L-Ser-OMe (69) in DMSO-d6 
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Appendix S 6: 
1
H NMR Spectrum of N-Fmoc-L-Phe-L-Oxazoline-OMe (72) in CDCl3 
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 Appendix S 7: 
13
C NMR Spectrum of N-Fmoc-L-Phe-L-Oxazoline-OMe (72) in CDCl3 
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Appendix S 8: COSY NMR Spectrum of N-Fmoc-L-Phe-L-Oxazoline-OMe (72) in CDCl3 
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Appendix S 9: DEPT 90 NMR Spectrum of N-Fmoc-L-Phe-L-Oxazoline-OMe (72) in CDCl3 
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Appendix S 10: DEPT 135 NMR Spectrum of N-Fmoc-L-Phe-L-Oxazoline-OMe (72) in CDCl3 
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Appendix S 11: 
1
H NMR Spectrum of N-Fmoc-L-Phe-L-Oxazole-OMe (68) in CDCl3 
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Appendix S 12:
 13 
C NMR Spectrum of N-Fmoc-L-Phe-L-Oxazole-OMe (68) in CDCl3  
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Appendix S 13: COSY NMR Spectrum of N-Fmoc-L-Phe-L-Oxazole-OMe (68) in CDCl3 
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Appendix S 14: DEPT 90 NMR Spectrum of N-Fmoc-L-Phe-L-Oxazole-OMe (68) in CDCl3 
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Appendix S 15: DEPT 135 NMR Spectrum of N-Fmoc-L-Phe-L-Oxazole-OMe (68) in CDCl3 
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Appendix S 16: 
1
H NMR Spectrum of N-Fmoc-D-Phe-Oxazole-OH (66) in DMSO-d6 
Signals marked with an X are due to dimethylaniline. 
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  Appendix S 17: 
1
H NMR Spectrum of N-Boc-L-Phe-L-Ser-OMe (82) in CDCl3 
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Appendix S 18:
 13
C NMR Spectrum of N-Boc-L-Phe-L-Ser-OMe (82) in CDCl3    
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Appendix S 19: DEPT 90 NMR Spectrum of N-Boc-L-Phe-L-Ser-OMe (82) in CDCl3 
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Appendix S 20: DEPT 135 NMR Spectrum of N-Boc-L-Phe-L-Ser-OMe (82) in CDCl3 
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Appendix S 21: 
1
H NMR Spectrum of N-Boc-L-Phe-Oxazoline-OMe (85) in CDCl3 
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Appendix S 22: 
13
 C NMR Spectrum of N-Boc-L-Phe-Oxazoline-OMe (85) in CDCl3 
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Appendix S 23: DEPT 90 NMR Spectrum of N-Boc-L-Phe-Oxazoline-OMe (85) in CDCl3 
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Appendix S 24: DEPT 135 NMR Spectrum of N-Boc-L-Phe-Oxazoline-OMe (85) in CDCl3 
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Appendix S 25: 
1
H NMR Spectrum of N-Boc-L-Phe-Oxazole-OMe (81) in CDCl3 
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Appendix S 26: 
13
 C NMR Spectrum of N-Boc-L-Phe-Oxazole-OMe (81) in CDCl3 
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Appendix S 27: COSY NMR Spectrum of N-Boc-L-Phe-Oxazole-OMe (81) in CDCl3 
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  Appendix S 28: DEPT 90 NMR Spectrum of N-Boc-L-Phe-Oxazole-OMe (81) in CDCl3 
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Appendix S 29: DEPT 135 NMR Spectrum of N-Boc-L-Phe-Oxazole-OMe (81) in CDCl3 
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Appendix S 30: 
1 
H NMR Spectrum of HClH2N-L-Phe-Oxazole-OMe (80) in DMSO-d6 
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Appendix S 31: 
13
 C NMR Spectrum of HClH2N-L-Phe-Oxazole-OMe (80) in DMSO-d6 
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Appendix S 32: COSY NMR Spectrum of HClH2N-L-Phe-Oxazole-OMe (80) in DMSO-d6 
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Appendix S 33: DEPT 90 NMR Spectrum of HClH2N-L-Phe-Oxazole-OMe (80) in DMSO-d6 
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Appendix S 34: DEPT 135 NMR Spectrum of HClH2N-L-Phe-Oxazole-OMe (80) in DMSO-d6 
 
102030405060708090100110120130140150160170
f1 (ppm)
-2000
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
1000013(14)(15)(16)DMSO.3.fid
1D 13C DEPT135 
CH, CH3 positive and CH2 negative (no quaternary carbons) 
NS: 4 * n, total number of scans
40
.0
7
40
.2
3
49
.3
8
52
.4
6
12
7.
74
12
9.
08
12
9.
59
14
6.
81
 
 
 
 
 
167 
 
 
 
 
 
 
Appendix S 35: 
1 
H NMR Spectrum of N-Boc-Phe-Oxazole-OH (79) in CDCl3 
Signals marked with an X are due to ethyl acetate. 
  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
9.
63
0.
62
2.
17
0.
72
0.
56
1.
82
4.
43
1.
00
1.
27
1.
28
1.
30
1.
32
1.
34
1.
41
 H
D
O
2.
07
3.
26
3.
27
3.
94
4.
12
4.
14
4.
15
4.
17
5.
13
5.
28
5.
86
7.
11
7.
24
 C
D
Cl
3
7.
25
7.
27
7.
28
7.
30
8.
24
79 
19
8 
1 
19
8 
4, 5, 6 + CDCl3 
198 
7 
19
8 
2 
19
8 
3 
19
8 
8 
19
8 
X 
19
8 
X  
19
8 
X  
19
8 
 
 
 
 
 
168 
 
 
 
 
 
 
 
 
Appendix S 36: 
13
 C NMR Spectrum of N-Boc-Phe-Oxazole-OH (79) in CDCl3 
Signals marked with an X are due to ethyl acetate. 
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Appendix S 37: COSY NMR Spectrum of N-Boc-Phe-Oxazole-OH (79) in CDCl3 
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Appendix S 38: DEPT 90 NMR Spectrum of N-Boc-Phe-Oxazole-OH (79) in CDCl3 
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Appendix S 39: DEPT 135 NMR Spectrum of N-Boc-Phe-Oxazole-OH (79) in CDCl3 
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Appendix S 40: 
1
H NMR Spectrum of N-Boc-L-Phe-L-Oxazole-L-Phe-Oxazole-OMe (78) in CDCl3 
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Appendix S 41: 
13 
C NMR Spectrum of N-Boc-L-Phe-L-Oxazole-L-Phe-Oxazole-OMe (78) in CDCl3 
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Appendix S 42: COSY NMR Spectrum of N-Boc-L-Phe-L-Oxazole-L-Phe-Oxazole-OMe (78) in CDCl3 
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Appendix S 43: DEPT 90 NMR Spectrum of N-Boc-L-Phe-L-Oxazole-L-Phe-Oxazole-OMe (78) in CDCl3 
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Appendix S 44: DEPT 135 NMR Spectrum of N-Boc-L-Phe-L-Oxazole-L-Phe-Oxazole-OMe (78) in CDCl3 
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Appendix S 45: 
1 
H NMR Spectrum of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-Phe-OH (76) in DMSO-d6 
Signals marked with an X are due to ethyl acetate. 
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Appendix S 46: 
13 
C NMR Spectrum of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-Phe-OH (76) in DMSO-d6 
Signals marked with an X are due to ethyl acetate. 
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Appendix S 47: 
1 
H NMR Spectrum of HClNH2-L-Phe-Oxazole-L-Phe-Oxazole-OMe (77) in DMSO-d6 
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Appendix S 48: 
13 
C NMR Spectrum of HClNH2-L-Phe-Oxazole-L-Phe-Oxazole-OMe (77) in DMSO-d6 
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Appendix S 49: 
1 
H NMR Spectrum of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe-Oxazole-OMe (75) in CDCl3 
Signals marked with an X are due to ethyl acetate. 
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Appendix S 50: 
13
 C NMR Spectrum of N-Boc-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe-Oxazole-OMe (75) in CDCl3 
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Appendix S 51: 
1 
H NMR Spectrum of HO-Oxazole-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe Oxazole-L-Phe-NH2 (74) in methanol-d4 
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Appendix S 52: 
13 
C NMR Spectrum of HO-Oxazole-L-Phe-Oxazole-L-Phe-Oxazole-L-Phe Oxazole-L-Phe-NH2 (74) in methanol-d4 
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Appendix S 53: 
1 
H NMR Spectrum of Macrocycle Oxazole-L-Phe-Oxazole-L-Phe- Oxazole-L-Phe-Oxazole-L-Phe (55) in CDCl3 
Signals marked with an X are due to diethyl ether solvent 
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Appendix S 54: 
13 
C NMR Spectrum of Macrocycle Oxazole-L-Phe-Oxazole-L-Phe- Oxazole-L-Phe-Oxazole-L-Phe (55) in CDCl3 
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